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ABSTRACT OF DISSERTATION

MUTATIONS OF FUS CAUSE AGGREGATION OF RNA BINDING PROTEINS,
DISRUPTIONS IN PROTEIN SYNTHESIS, AND DYSREGULATION OF
NONSENSE MEDIATED DECAY
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease
characterized by motor neuron death and subsequent muscle atrophy. Approximately 15%
of ALS cases are inheritable, and mutations in the Fused in Sarcoma (FUS) gene contribute
to approximately 5% of these cases, as well as about 2% of sporadic cases. FUS performs
a diverse set of cellular functions, including being a major regulator of RNA metabolism.
FUS undergoes liquid- liquid phase transition in vitro, allowing for its participation in
stress granules and RNA transport granules. Phase transition also contributes to the
formation of cytoplasmic inclusions found in the cell bodies of FUS ALS patients motor
neurons. The nature of these inclusions has remained elusive, as the proteins localized to
them have not been identified. Additionally, the functional consequence of the
accumulation of cytoplasmic FUS inclusions has not been established, nor is it understood
how they contribute to selective motor neuron death.
We carried out two related, but independent studies to characterize the proteins that
may be included in FUS-positive inclusions. In this first study, we utilized
immunoprecipitation of wild-type and mutant FUS in the presence and absence of RNase,
followed by LC MS/MS. The identified proteins represent those that directly or indirectly
interact with FUS, with relatively high affinity that can be pulled down with
immunoprecipitation. A wide variety of interacting proteins were identified and they are
involved in a multitude of pathways including: chromosomal organization, transcription,
RNA splicing, RNA transport, localized translation, and stress response. Their interaction
with FUS varied greatly in their requirements for RNA. Most notably, FUS interacted with
hnRNPA1 and Matrin-3, proteins also known to cause familial ALS. Immunofluorescent

staining of proteins interacting with mutant FUS were localized to cytoplasmic inclusions.
We concluded that mis-localization of these proteins potentially lead to their dysregulation
or loss of function, thus contributing to FUS pathogenesis.
In the second study, we developed a protocol to isolate dynamic FUS inclusions
and employed LC MS/MS to identify all proteins associated with FUS inclusions. We
identified a cohort of proteins involved in translation, splicing, and RNA export to be
associated with the FUS inclusions. Further pathway and disease association analysis
suggested that proteins associated with translation and RNA quality control pathways may
be the most significant. Protein translation assays using both N2A and ALS patient
fibroblasts demonstrated suppression of protein biosynthesis in mutant FUS expressing
cells. However, translation initiation was not impaired. To understand how protein
synthesis is suppressed by mutant FUS mediated defects in RNA metabolism, we examined
changes in a well conserved RNA turnover pathway namely: nonsense mediated decay
(NMD). We found that NMD is hyperactivated in cells expressing mutant FUS, likely due
to chronic suppression of protein translation shifting the pathways autoregulatory circuit to
allow for hyperactivation. We concluded that mutant FUS suppresses protein biosynthesis
and disrupts NMD regulation. These defects together likely contribute to motor neuron
death.
KEYWORDS: Fused in Sarcoma, Amyotrophic Lateral Sclerosis, RNA binding, Nonsense
Mediated Decay, Protein Translation.
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CHAPTER 1. INTRODUCTION
1.1

What is Amyotrophic Lateral Sclerosis?
Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressing, neurodegenerative

disease impacting both upper and lower motor neurons. Brought into the public eye in the
1930s by the American baseball player, Lou Gehrig, the disease is characterized by bodywide voluntary muscle weakness and paralysis, culminating in the death of the patient (1).
According to the ALS Association, in the United States alone, there are approximately
20,000 individuals living with ALS and 6,000 new diagnoses each year. ALS can be
classified as sporadic (sALS), where no family history of the disease is found, or familial
(fALS) if a mutated allele is identified in several family members with the disease. Roughly
90% of ALS cases are considered sporadic, while the remaining 10% are from inheritable
mutations. Genes most commonly mutated that result in an ALS phenotype are C9orf72,
Superoxide Dismutase I (SOD1), transactive response DNA binding protein 43 kDa (TPD43), and Fused in Sarcoma (FUS) (1).
FUS is a DNA and RNA binding protein identified in 2009 to cause approximately
5% of fALS and 2% of sALS cases when mutated (2, 3). Although FUS mutations are
considered rare and only account for 5% of fALS cases, it accounts for approximately 60%
of all fALS cases for patients younger than 40 years of age (4, 5). The severity of FUS
related ALS varies, with specific mutations resulting in a shorter course of disease earlier
in life. Severe, disease-causing mutations typically result in FUS’ mis-localization from
the nucleus to the cytoplasm. Presentation of FUS in the cytoplasm can vary in appearance,
depending on the type of mutation an individual has (5). Mutant FUS’ presentation in the
1

cytoplasm may range from diffuse throughout the cytoplasm to forming large inclusion
bodies. These inclusions are basophilic, and ubiquitin and p62 positive (6, 7), however, the
consequence of their formation in the cell body of motor neurons is unknown. Wild type
FUS’ cellular functions have been well characterized and include transcription, regulation
of RNA length, alternative splicing, nucleocytoplasmic export, protein translation, and
maintenance of RNA stability.

1.2

FUS’ Domain Structure and Post Translational Modifications
FUS is a member of the FUS, EWSR1, TAF15 (FET) family of DNA and RNA

binding proteins. These proteins are composed of a unique set of a prion-like QGYS
domains, two RNA-recognition motifs (RRM), a zinc-finger (ZnF) domain, and a Cterminal nuclear localization domain (5). To better understand FUS’ molecular function,
several in-depth studies have been conducted to understand the importance of each domain.
FUS’ QGYS, or low-complexity (LC), domain has been characterized using NMR. It was
determined to have a unique amino acid profile and folding dynamics compared to many
other intrinsically disordered, neurodegenerative proteins (8). FUS’ QGYS domain is
required for formation of functional oligomeric species that can be regulated through
phosphorylation of serine and threonine residues. Phosphorylation of these sites facilitates
disassembly of liquid/liquid droplets formed by FUS and prevent its aggregation (8, 9).
RNP granules formed through the QGYS domain are critical for regulation of mRNA
stability, location, and metabolism, most notably the formation of stress granules (SGs) in
times of acute cellular stress (10-12).

2

In addition to self-oligomerization being required for RNP granule formation and
binding RNA polymerase 2 (RNAP2), RNA binding is also needed for seeding these
complexes (13, 14). FUS’ nucleotide (DNA and RNA) binding function is executed
through its RGG, RRM and ZnF domains (15, 16). Little is understood about the
mechanism through which the domains determine nucleotide binding specificity, however,
this aspect of FUS’ structure is central to its natural cellular function, as well as its disease
phenotype. FUS’ RGG and RRM domains can be methylated on arginine residues.
Arginine methylation is important for regulating FUS’ participation in phase separation
and transportin-1 (TNPO1) binding. It has been reported that disruption of FUS’
methylation profile, characteristic of FUS mutations contributes to cytoplasmic mislocalization and stabilization of oligomeric structures (17, 18). Together, FUS’ amino acid
sequence, domains, and types of post-translational modifications are critical for its
localization and function in motor neurons (Fig. 1.1). Disturbance in one of these features
due to an ALS causing mutation leads to gross changes in FUS’ molecular function and
contributes to a neurodegenerative phenotype.

1.3

FUS’ Nuclear Function
FUS is largely a nuclear protein that plays critical roles in transcription, mRNA

maturation, and nucleocytoplasmic export of RNA (Fig. 1.2). It is hypothesized that the
first step in cellular dysfunction contributing to ALS pathogenesis is FUS’ exclusion from
the nucleus (19). Exclusion of FUS from the nucleus may result in defective transcription,
polyadenylation, and splicing of mRNA. FUS’ structure is critical to its normal function in
the nucleus and is vital to maintaining the fidelity of the transcriptome.
3

Transcription

FUS is a potent regulator of RNA synthesis that can bind active chromatin. There
are two nuclear pools of FUS: a soluble fraction and chromatin bound fraction (20). It is
likely that the chromatin bound fraction contains FUS interacting with RNAP2 and directly
with DNA. The soluble fraction is FUS bound to newly synthesized RNA, regulating
splicing and processing mRNA for nuclear export (20). These observations are supported
by FUS knockout experiments that describe lost expression of hundreds of genes (21).
Additionally, formation of oligomeric species is required for WT and mutant FUS to
interact with active chromatin in discreet nuclear puncta (20, 22), indicative of localization
to sites of active transcription (23). Mutations that lead to exclusion of FUS from the
nucleus have fewer active sites and repression of transcription (20, 22).
FUS’ interaction with RNAP2 is critical for its role in the regulation of gene
expression. Accumulation of FUS at transcriptional start sites (TSS) recruits RNAP2 to
active chromatin (20, 22). Following recruitment, FUS binds the C-terminal domain (CTD)
of RNAP2, where it regulates its phosphorylation state of specific serine residues.
Classically, there are two positions within the CTD that promote or block RNAP2
translocation along DNA: serine 2 (Ser2) and serine 5 (Ser5). Upon FUS knockdown,
studies demonstrated the accumulation of phosphorylation on Ser2 (13) (p-Ser2), which is
illustrative of transcriptional termination (24, 25). These knockdown studies demonstrated
that FUS limits p-TEFb phosphorylation of Ser2, implying that FUS functions to prevent
premature termination of transcription (13). However, as RNAP2 travels down the DNA,
p-Ser2 collects on the CTD, which eventually displaces FUS and terminates transcription
4

(26). Studies in ALS patient fibroblasts exhibited similar changes in the phosphorylation
state of Ser2 as observed in FUS knockdown cells, indicating that mutations in FUS result
in a nuclear loss of function (23). Mutant FUS has been observed to localize within nuclear
aggregates sequestered away from TSS’ and RNAP2. This sequestration away from
transcriptionally active chromatin and RNAP2 likely leads to premature phosphorylation
of Ser2 near the TSS and reduced mRNA levels (23).
Deeper explorations of differences between how mutant and WT FUS bind
transcriptionally active chromatin demonstrate the importance of oligomerization and
RNA binding. Both forms of the protein bind chromatin through their LC-domains and
RNA through FUS’ RGG-Zn-RGG domains (13, 27). However, compared to WT FUS,
mutant FUS has reduced chromatin binding capabilities, and therefore some loss of nuclear
function (20). In fact, FUS’ LC-domain is required for interaction with chromatin, binding
RNAP2, and effective transcription, suggesting that formation of functional oligomers is
intrinsic for FUS’ nuclear function (20).
Taken together, FUS is an important regulator of transcription through several
different modalities. Endogenous FUS influences transcriptional activity through directly
binding to chromatin and to RNAP2. These interactions are critical to signal for
transcription to be initiated for a specific gene, but also to enhance complete RNA
synthesis.

5

Regulation of mRNA Length and Coupling Transcription to Splicing

FUS plays an important role in post-transcriptionally modifying mRNA to control
gene expression in tandem with transcription. Connection of transcription to mRNA
splicing and polyadenylation is an important step in efficient maturation of mRNA.
Without these processes, transcription would terminate prematurely, and newly
synthesized mRNA would undergo premature polyadenylation (28, 29).
FUS is a potent regulator of mRNA length through selection of favorable
polyadenylation sites for expression of approximately two-thirds of neuronal genes (30).
FUS’ binding to nascent RNA, in combination to direct interaction with RNAP2,
determines

transcriptional termination

and

polyadenylation

(30).

To

regulate

polyadenylation, FUS binds upstream (5’) or downstream (3’) of alternative
polyadenylation (APA) sites (30). The location of FUS’ binding site on RNA determines
whether the short polyA or degraded isoform is favored. For short APA isoforms, FUS
binds downstream (3’) from the APA site, which enhances the RNA’s interaction with
RNAP2, allowing polyadenylation specificity factor (CPSF) complex members to bind,
specifically, CPSF160. This interaction generates short polyA tails and stimulates
additional proteins to bind and finish synthesizing sequence (31, 32). Conversely, if FUS
binds upstream (5’) of an APA site, RNAP2 stalls and terminates transcription, leading to
truncated transcripts that are degraded (30).
Studies exploring the consequences of FUS’ loss of function in motor neurons
demonstrated dysregulation of transcription and polyadenylation (30, 33). For example,
FUS knockdown caused APA sites to be differentially regulated for genes relating to
6

synaptic activity and motor neuron-specific activity (30). More research needs to be done
looking into changes in transcription and polyadenylation that occur when FUS is mutated
to gain a deeper understanding of how ALS mutations of FUS directly the transcriptome.
Alternative Splicing

FUS’ interaction with RNA is complicated; several different groups have identified various
sequences and secondary characteristics that FUS preferentially interacts with, however,
an agreement as to FUS’ specificity has not been reached in the field. Preliminary studies
identified a GGUG consensus sequence that facilitated FUS binding through its RRM
domain (34, 35). Advancements in technology have allowed us to identify specific
secondary structures and G/C or A/U rich regions FUS also binds (21, 36, 37). Although
no definitive sequence FUS binds to has been identified, the protein broadly clusters around
the 5’ ends of long introns (21, 30, 37, 38), as well as within introns of cassette exons (30,
39).
This consistent binding pattern of FUS to binding 5’ ends of introns and within
cassette exons illustrates FUS’ important role as a regulator of alternative splicing.
Explorations of functional defects caused by FUS knockout in neurons demonstrated
changes in splicing of over 3,000 exons and expression changes in 183 genes (30). Of the
183 genes exhibiting the most significant alterations in their splicing profiles, several were
involved in neuronal function and neurodegeneration. They include Mapt, Camk2a, and
Fmr1 (30). Additionally, annotation enrichment of genes regulated by FUS, demonstrated
its importance in neuronal gene expression. Terms such as “neuronal impulse”, “neuronal
projection”, and “vesicle transport” were enriched (30). Studies investigating FUS’ binding
7

pattern within introns demonstrated enrichment within genes of RNA binding proteins in
mouse and human brains, as well. The intronic sequences FUS binds are highly conserved
and upon FUS knockout, are retained within the mature mRNA (35). Overall, FUS’ binding
of introns is required for normal expression of genes required for neuronal function and
RNA metabolism. However, FUS’ ability to regulate splicing is done in conjunction with
other splicing factors.
FUS’ role in regulation of splicing largely involves its interaction with U1snRNP
and other splicing factors (40-43). Perhaps one of FUS’ best-understood protein/protein
relationships is between U1snRNP and Survival Motor (SMN), the protein responsible for
Spinal Muscular Atrophy (SMA). U1snRNP is a core spliceosomal component responsible
for recognizing the 5’ splice site of an intron, the first step in the classical splicing pathway
(44). During transcription, FUS recruits U1snRNP to 5’ ends of introns to begin assembly
of splicing complex members (45). Studies utilizing ALS FUS mutants observed reduction
of U1snRNP/pre-mRNA interaction. This is likely due to defective interactions between
mutant FUS and U1snRNP, U1snRNP’s mis-localization to the mutant FUS inclusion, and
an overall reduction of U1snRNA bioavailability due to defective SMN activity (40, 41).
SMN is considered to be the master of snRNP biogenesis (46) and mRNP assembly
on pre-mRNA (47, 48), however, this is not without the help of FUS. WT and mutant FUS
have been shown to directly bind to SMN and SMN complex members (42). Mutations in
FUS disturb SMN’s localization due to sequestration of SMN in cytoplasmic FUS
inclusions, thus reducing its nuclear availability and the number of Gems (40, 42). Gems
are SMN-dependent sites of snRNA biosynthesis (49). Mutations in FUS mimic the same
8

loss of Gems observed in FUS KO cells, resulting in the reduction in snRNA synthesis.
These patterns are observed in patient fibroblasts, transfected cells, and in transgenic
mouse models of FUS ALS (40, 42). This is likely due to reductions in the levels of select
snRNAs. In addition to disrupting snRNP biogenesis, in a mouse motor neuron model of
mutant FUS, localization of SMN to cytoplasmic inclusions leads to reduced axonal SMN,
contributing to axonal defects (50).
Together, interaction between mutant FUS, U1snRNP, and SMN illustrate the
detrimental effects that occur when FUS is mutated. FUS mutations lead to a complex
cytoplasmic toxic gain of function/nuclear loss of function phenotype across disease
models. FUS’ toxic sequestration of U1snRNP and SMN in cytoplasmic inclusions
contributes to splicing defects illustrative of nuclear loss of function. Overall, the splicing
defects that arise for loss of snRNPs and FUS are vast, negatively impact normal neuronal
function, and are likely to be a main contributor to motor neuron degeneration.
FUS’ role in splicing is not limited to the classical U1 splicing pathway (5, 21, 33,
35, 37-39, 51, 52). FUS also plays a role in splicing U12-type introns of the minor splicing
pathway (53). These unique introns comprise approximately 1% of the transcriptome. Of
the small subset of transcripts that are included in this group, a member of the voltagegated sodium channel required for normal muscle function is included (54, 55). In a
mechanism similar to U1snRNP dependent splicing, FUS binds the 5’ splice site of introns
to recruit U11 (53). Moreover, mutations in FUS fail to recruit U11 and U12 to the premRNA and traps them in cytoplasmic inclusions (53).
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Finally, FUS also plays a role in regulation of the circular RNA (circRNA)
transcriptome. circRNAs are a rare species of RNA that originate from back-splicing events
in which a downstream 5’ splice site covalently binds with the upstream 3’ splice site (56).
Their functions in the cytoplasm of cells are still elusive, however, they are thought to act
as “sponges” for RBPs to regulate their activity (57). In IPSC derived motor neurons
deficient for FUS, 134 different circular transcripts were discovered to be differentially
regulated, with 111 being downregulated. In N2a cells expressing FUS P525L and R521C
ALS mutations, the same pattern of circRNA downregulation was recapitulated, likely due
to nuclear deficiencies in splicing factors. Further inquiry into FUS’ role in the
circularization mechanism demonstrated that FUS must bind introns flanking the
circularized exons (58). This is consistent with data demonstrating that FUS is required to
bind along introns for alternative splicing to occur (20, 21, 39, 51, 56).
Overall, many studies have illustrated FUS’ critical importance in regulating gene
expression. This regulation and control span from snRNA biogenesis through interaction
with SMN, to generation of rare circRNA isoforms. FUS’ function in binding the 5’ end of
introns to recruit splicing factors from the classical and minor splicing pathways
demonstrate its broad impacts on neuronal gene expression. Changes in gene expression
and splicing may provide the initial steps in a complex pathogenic mechanism culminating
in motor neuron death.

1.4

Nucleocytoplasmic Shuttling of FUS
A pathological hallmark of FUS-ALS is accumulation of FUS in cytoplasmic

inclusion bodies in the somas of motor neurons (2, 3). A long-standing question the field
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aimed to answer was how and why FUS mutants remain localized to the cytoplasm and
formed potentially pathological inclusions. An interesting feature of FUS is its noncanonical nuclear localization sequence (NLS) that binds TNPO1 (59, 60) through
methylation in its RGG3 domain (18, 61). TNPO1 transports FUS back into the nucleus
through the nuclear pore complex upon its release from mRNA in the cytoplasm. Mutations
in FUS, however, impair its TNPO1 interaction due to defective methylation (12, 18, 62,
63). FUS’ regulation through methylation is a complicated set of events dictated by
PRMT1 asymmetrically dimethylating FUS. Monomethylated FUS has a much higher
affinity for TNPO1 and may be responsible for cytoplasmic sequestration of TNPO1
characteristic of FTLD-FUS (18, 64). In contrast, mutant FUS is hypomethylated in ALS,
which results in cytoplasmic aggregation (17, 19, 62). It is speculated that neuron sub-type
specific changes in methylation enzymes account for differences between FTLD and ALS
(17).
Further research into the mechanism that regulates FUS’ re-entry to the nucleus
illustrates that binding of TNPO1 to FUS’ NLS prevents phase separation required to form
cytoplasmic aggregates (18). FUS mutants are prone to aggregation due to their reduced
ability to interact with TNPO1 (18, 65). FUS’ low complexity N-terminal domain naturally
forms β-sheets through arginine and tyrosine residues interacting via cation-π interactions
(17). Hypomethylation of these residues promotes phase separation, as it prevents TNPO1
from acting as a molecular chaperone for FUS in the axons of motor neurons, as well as
the nuclear pore (17).
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1.5

FUS’ Cytoplasmic Function
FUS’ cytoplasmic role in neurons has yet to be described in detail. Recent

publications have begun to describe FUS’ role in regulation of stress granule dynamics,
translation, and regulation of mRNA stability (Fig. 1.3).
Protein Translation

FUS’ function in regulation of mRNA metabolism is ever evolving. FUS has been
demonstrated to be shuttled out into the cytoplasm bound to mRNA, then chaperoned back
into the nucleus. Early in FUS’ characterization, it was linked to translation in adenomatous
polyposis coli (APC)-RNPs. These granules included RNAs that mediate cell migration.
Interestingly, both wild type and mutant FUS were localized to these translationally active
granules in cell protrusions (66), however, the levels of protein biosynthesis were not
measured.
More recently, FUS’ cytoplasmic function has begun to be described in more detail.
Transgenic mice expressing wild type or the R521 mutant were observed to have defects
in axonal translation and changes in RNA expression. Specifically, it was reported that
elevated levels of RNA’s encoding for stress-related chaperones were observed, while
genes for synaptic function like ion transporters were downregulated (67). This landmark
paper provides support and a mechanism to a 2015 paper demonstrating the GluA1 subunit
of the AMPA receptor is downregulated (68). Both groups described behavioral deficits in
mutant animals, while only the Da Cruz lab identified motor defects. This fascinating
difference in phenotype is likely due to different neuronal subtypes bearing mutations (67,
68).
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RNA Triage and Stress Response

FUS involvement in stress granule (SG) formation has been described as a vital function
of the protein since it was initially implicated in causing ALS. SGs are membrane-less,
cytoplasmic granules that are sites of arrested translation and temporary mRNA
stabilization. They function to protect mRNP complexes in times of acute cellular stress.
Many proteins are recruited into SGs, including wild type and mutant FUS (12, 69). Studies
that aimed to understand FUS’ role in SG formation utilized FUS KO cells. Ultimately, it
was found that loss of FUS does not negatively impact SG formation, indicating that FUS
participates in later stages of stress response and RNA triage (69).
To investigate the mechanism by which wild type and mutant FUS localize to the
cytoplasm, Pandey et.al mutated four phenylalanine residues (F305, F341, F359, and F368)
to leucine in FUS’ RRM (11). Mutation of these residues abolished FUS’ RNA binding
ability and resulted in nuclear sequestration of FUS, suggesting that RNA binding is
required for FUS’ nuclear export and incorporation into SGs (11). Mutant FUS follows
similar rules for SG incorporation, requiring RNA binding to enter SGs, however, it is
hypothesized that this initiates the formation of cytoplasmic inclusions. Additionally, FUS
cannot act alone in managing SGs dynamics. Proteins like G3BP1 and TIA1 also manage
the longevity, size, and mRNA stability with SGs (70, 71). Changes in the SG proteome
can account for differences when comparing their formation in WT and mutant FUS cells.
However, the mechanism driving the potential stabilization of SG’s in cells bearing mutant
FUS is unknown.
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A large variety of proteins can be found localized to the SG- like mutant FUS
inclusions, however, many are related to RNA binding, SG formation, protein translation,
and other aspects of RNA metabolism. Early proteometric analysis of FUS’ binding
partners identified a number of key stress granule proteins, including Poly-A binding
protein (PABP1). Additionally, FUS inclusions also colocalize with SG markers TIA1,
Caprin-1, and G3BP1 (70, 72-74). P-bodies are observed adjacent to FUS inclusions,
suggesting that stabilized SGs are sites of RNA decay (72). The molecular functions of
these proteins in SG’s remain elusive, however, they are vital to normal stress response.
One RNA binding protein that interacts with mutant FUS and whose function in
the SG-like inclusions has been explored is Pur-alpha (75). Pur-alpha is a single-strand
DNA binding protein found to localize to SGs when FUS is mutated (75, 76). In cells
expressing mutant FUS, Pur-alpha overexpression has been demonstrated to play a
protective role by preventing FUS’ cytoplasmic mis-localization to SGs, thus preventing
the formation of large inclusion bodies and toxicity (75).
As SG formation is thought to be a precursor event to inclusion formation, more indepth studies must be performed. A more complete understanding of the interaction mutant
FUS has with proteins and RNAs localized in SG-like inclusion bodies will illustrate the
proteins whose function is most impacted by FUS mutations (11, 77).
Regulation of RNA Stability

A burgeoning avenue of research delving further into FUS’ cytoplasmic function is its role
in managing mRNA stability. Two different mechanisms have arisen to be controlled by
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FUS to influence the stability of select RNA species: miRNA targeting and Nonsense
Mediated Decay (NMD).
FUS has been established to control miRNA biogenesis for mRNAs required in
neuronal development and activity through recruitment and loading of Drosha onto primiRNA upon transcription (78). Drosha is a critical enzyme in the miRNA biogenesis
pathway required to cleave pri-miRNA to pre-miRNA (79). Upon FUS knockdown, the
levels of miR-9, miR-125b, and miR-132 are all down-regulated. Loss of these miRNA
species is thought to be due to defective processing of pri-mRNA due to FUS KO. These
miRNA species have a key role in neuronal function, differentiation, and synaptogenesis,
respectively (78). Loss of these miRNA results in toxic increases of neuronal proteins.
Mutations in FUS, specifically FUS P525L and equivalents, can result in severe
disturbances in levels of the miRNA landscape due to their exclusion from the nucleus. For
example, mutations result in upregulation of brain-specific miR-409-3p and miR-495-3p
(80). Upregulation of these miRNAs is related to a number of neurodevelopmental
disorders involved down-regulation of Gria2, a subunit of the AMPA receptor. Loss of this
subunit results in excitotoxic events leading to defective Ca2+ regulation (80). miRNA
species can also participate in the autoregulatory loops of many RNA binding proteins (81).
In spinal motor neurons of ALS patients, miR-b2122 expression is depressed and thought
to regulate TDP-43, FUS/TLS and RGNEF (81). Down-regulation of this miRNA in
sporadic ALS patients may result in toxic overexpression of these proteins
In addition to regulating mRNA levels through miRNA binding and silencing,
NMD has been identified to play an important role in influencing neurotoxicity in FUS
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models. In early yeast studies, it was demonstrated that overexpression of UPF1 rescued
mutant FUS toxicity (82). Further confirmation of NMD’s importance in mediating
neuronal toxicity was demonstrated in a mouse neuronal model of ALS, where
overexpression of UPF1 within a particular range, was neuroprotective (83). A deeper
understanding of how NMD participates in regulation of mRNA stability will be a
fascinating avenue of study for the ALS field. Research of this pathway in relation to FUS
ALS may provide many links to other molecular mechanisms thoroughly researched by the
field, including mRNA splicing and protein translation.

1.6

Study Rationale and Overview
A well-defined molecular mechanism driving FUS ALS remains elusive. We aimed

to demonstrate a novel mechanism that explored reported defects in RNA metabolism and
to understand how they are related to the FUS inclusions. Proteins localized to the mutant
inclusions had not been identified or characterized. It had been widely speculated that
mutant FUS inclusions are stalled and/ or ultra-stable stress granules, however, a functional
consequence of their stasis has not been ascribed to them. Additionally, early studies began
to illustrate a link between FUS and protein translation. Until 2018, however, no efforts
had been made in the field to further explore protein translation in ALS or its relationship
with the mutant FUS inclusion. Overall, our goal was to understand the role mutant FUS
inclusions play in protein translation and mRNA stability.
To address this, we designed two exploratory mass spectrometry studies to first
characterize the mutant FUS inclusions: 1) to examine direct FUS interactors dependent
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and independent of RNA binding and 2) proteins exclusively associated with the inclusion.
These studies illustrated the link between mRNA stability, regulation of stress granule
dynamics, and protein translation. From these data we proposed two hypotheses:
1. FUS mutations sequester stress granule proteins in inclusion bodies, impairing their
function.
2. FUS inclusions are sites of stalled or terminated translation complexes and mRNA
degradation by NMD.
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Figure 1.1 FUS Domain Structure
RGG, Arginine/glycine-rich region; RRM, RNA recognition motif; ZnF, zinc finger
domain; NLS, nuclear localization sequence. R495X, R521G, P525L, and P525R are
naturally occurring ALS mutations.
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Figure 1.2 FUS Nuclear Functions
FUS binds transcriptionally active DNA directly, as well as on the C-terminal domain of
RNAP2. When bound to RNAP2, FUS functions to prevent phosphorylation of Ser 2,
preventing premature termination of transcription. FUS also binds pre-mRNA, facilitating
formation of U1snRNP and SMN spliceosomal complexes. After splicing is complete, FUS
19

Figure 1.2 Continued
is exported from the nucleus on mRNA, into the cytoplasm. FUS dissociates from the
mRNA, binds TNPO1, and is shuttled back into the nucleus.
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Figure 1.3 FUS' Cytoplasmic Function
FUS has several cytoplasmic functions related to maintenance and regulation of mRNA
stability, and protein translation. FUS plays a role in stress granule dynamics, allowing for
21

Figure 1.3 Continued
disassembly of the temporary structures once acute stress is resolved. FUS also plays an
elusive role in regulation of translation and axonal protein biosynthesis. Additionally, FUS
aids in preventing miRNA decay of cytosolic transcripts, facilitating expression of specific
genes.
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CHAPTER 2. MATERIALS AND METHODS
2.1

Cell Culture, Plasmids, and Transfection
The HEK293T (293T) and N2a cells were cultured in Dulbecco's Modified Eagle's

Medium (Sigma-Aldrich, D5796) with 10% fetal bovine serum and penicillin-streptomycin
at 37 °C in 5% CO2/95% air. The SH-SY5Y cells were cultured in a 1:1 mixture of
Dulbecco's Modified Eagle's Medium/F-12 Ham (Sigma-Aldrich, D8437) with 10% fetal
bovine serum and penicillin-streptomycin at 37 °C in 5% CO2/95% air. The 293T cells
were transfected with Polyethylenimine “Max” (Polysciences, Inc.). The SH-SY5Y and
N2a cells were transfected with Lipofectamine 2000 (Life Technologies, 11668). The
pCMV10 3X FLAG FUS and pEGFP-C3 FUS plasmids used were created for previous
studies (72). The Polio IRES luciferase translation reporter construct was a generous gift
from Dr. Tianyan Gao (84). βWT, β39, GPX-1 WT, and GPX-1 PTC NMD reporters were
a gift from Dr. Jens Lykke-Andersen.

2.2

Culture and Transfection of Primary Cortical Neurons
The mouse primary cortical neuron cultures were prepared as reported (85). Briefly,

neonatal mouse pups (strain C57BL/6, Jackson Laboratory) were sacrificed via
decapitation within 24 h of birth. The cells were maintained in Neurobasal Medium (Life
Technologies, 21103049) with B27 supplement (Life Technologies, 17504044), lglutamine and penicillin/streptomycin. Neurons were dissociated from glial cells using
pipette lavage after incubation with trypsin. The cells were treated with 5-Fluoro-2′deoxyuridine (Sigma-Aldrich, F0503). Fourteen days after 5-Fluoro-2′-deoxyuridine
treatment, the primary neurons were transfected with EGFP-tagged WT or P525L mutant
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FUS expression constructs using Lipofectamine 2000 (Life Technologies, 11668). The
primary neurons were fixed 48 h post-transfection for immunofluorescence.

2.3

GST-FUS Pull-Downs
The GST-FUS pull-downs were performed similarly as reported before (72).

Briefly, the wild type, R521G or P525L mutant human FUS coding sequences were
inserted into the pEBG glutathione S-transferase (GST) fusion vector (86) using
the BamHI and KpnI sites. pEBG was a gift from Dr. David Baltimore (Addgene plasmid
# 22227). 293T cells were transfected with the GST-FUS constructs. Two days posttransfection, cell lysates were prepared in 1 × RIPA buffer (Millipore, 20-188)
supplemented with protease inhibitor cocktail (Sigma, P-8340, 1:500) and 1 mM sodium
orthovanadate with syringe homogenization. The lysates were pre-cleared with Sepharose
CL-4B (Sigma, CL4B200), then subjected to overnight pull-down with Glutathione
Sepharose 4B (GE Healthcare, 17-0756-01). Where indicated, a cocktail of RNase A and
RNase T1 (Life Technologies, AM2286) was added to the pre-cleared lysates before the
pull-down at 1:100 dilution. The bound proteins were eluted by boiling with Laemmli
sample buffer (Bio-Rad, 161-0737).

2.4

Immunoprecipitation
Cellular extracts of SH-SY5Y or N2a cells were prepared in 1 × RIPA buffer

(Millipore, 20-188) supplemented with protease inhibitor cocktail (Sigma, P-8340, 1:500)
and 1 mM sodium orthovanadate with syringe homogenization. The cellular lysates were
first pre-cleared with Protein G UltraLink Resin (Thermo Scientific Pierce, 53126), then
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incubated with antibody against bait protein (Santa Cruz, sc-47711) and Protein G
UltraLink Resin overnight. The negative control immunoprecipitation antibody was mouse
anti-HA (Santa Cruz, sc-7392) or normal goat serum. The bound proteins were eluted by
boiling with Laemmli sample buffer (Bio-Rad, 161-0737) or eluted using FLAG peptide.

2.5

Proteomic identification of FUS interaction partners
The proteins eluted from the Glutathione Sepharose 4B beads were resolved by

denaturing polyacrylamide gel electrophoresis (SDS-PAGE) on 4–15% gradient gel,
followed by staining with Sypro Ruby protein gel stain (Molecular Probes, S-12000). Each
lane was cut into 20 slices of equal size and each slice was subjected to in-gel trypsin
digestion (87). The resulting tryptic peptides were extracted and subjected to liquid
chromatography-tandem mass spectrometry (LC-MS/MS) using an LTQ Orbitrap Velos
mass spectrometer (Thermo Scientific). The LC-MS/MS results were processed with a
local Mascot server (version 2.3, Matrix Science) for protein identification including
methionine oxidation and cysteine carbamidomethylation as allowed side chain
modifications. The LC-MS/MS data of the 20 slices were combined for protein
identification using the MASCOT algorithm. False discovery rate of 1% was used in decoy
search for the high-confidence peptides. Proteins with a score of at least 30 for single highconfidence peptides were considered positive identifications. MS/MS spectra of highconfidence peptides with scores lower than 50 were manually inspected and confirmed.
UniProt protein names and identifier numbers are used throughout this work (88).
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2.6

Western Blot
The nitrocellulose membranes were blocked, and antibodies were applied in 5%

milk in TRIS-buffered saline/Tween-20 (TBST, 0.1 M TRIS-HCl, 0.9% [w/v] NaCl, 0.1%
[v/v] Tween-20, pH 7.5). The antibodies used were anti-NF45/ILF2 (Bethyl, A303-147AM), anti-DHX9 (Bethyl, A300-855A-M), anti-Matrin-3 (Bethyl, A300-591A-M), antihnRNPA1 (Novus, NB100-672), anti-Caprin-1 (Proteintech, 15112-1-AP), anti-GST
(Santa Cruz, sc-459), anti-DDX3X (Sigma, HPA001648), anti-actin (Santa Cruz, sc-1616),
anti-FLAG (Sigma, A8592., anti-eIF4A1 (Cell Signaling, 2490), anti-eIF4G (Cell
Signaling, 2469), anti-eIF4E (Cell Signaling, 9742), anti-eIF3 (Santa Cruz, sc-74507), antieIF4A3 (ProteinTech, 17504-1-AP), anti-RPS6 (Cell Signaling, 2217), anti-G3BP1
(ProteinTech, 13051- 2-AP), anti-RPL7a (Cell Signaling, 2415), anti-K48 TUBE (Tandem
Ubiquitin Binding Entity, LifeSensors, UM305), anti-K63 TUBE (LifeSensors, UM304),
anti-pan ubiquitin (Santa Cruz, sc8017), anti-HA (Santa Cruz, sc-805), anti-UPF1 (Bethyl,
A300-038A), anti-phospho Ser/Thr 4 ATM/ AMR substrate (i.e. p-S/T, Cell Signaling,
2851), anti- phospho UPF1 S1089 (Millipore 07-1015), anti-PABP1 (Santa Cruz, sc32318), anti-eRF3b (Santa Cruz, 515615), anti-BrdU (Abcam, ab6326), anti-p62
(ProteinTech, 18420-1-AP) anti-Actin (Santa Cruz, sc-81178), antiGAPDH (Santa Cruz,
sc-32233), anti-puromycin (Millipore, MABE343), anti-UPF3a (Proteintech, 17114-1AP), anti-XRN1 (Bethyl, A300-443A-M), Anti-UPF3b (Invitrogen, PA5- 51652), antiSMG6 (Abcam, ab87539), anti-SMG1 (Abcam, ab30916), anti-SMG5 (ThermoFisher,
PA5-44295), anti-SMG7 (ThermoFisher, PA5-38140), anti-RNPS1 (PA5- 35967), and
anti-FUS (Santa Cruz, sc-47711). The immunoblotting images were acquired with the
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Chemidoc MP Imaging System (Bio-Rad) and quantified with the Image Lab software
(Bio-Rad).

2.7

Immunofluorescence microscopy
SH-SY5Y or N2a cells were seeded on gelatin-treated glass coverslips and

transfected with EGFP-tagged FUS constructs (72). After 48 hours, the cells were fixed in
4% (w/v) paraformaldehyde in 1 × PBS, permeabilized with 0.25% (v/v) Triton X- 100 in
1 × PBS and blocked with 10% (w/v) bovine serum albumin (BSA) in 1 × PBS. The slides
were incubated with primary antibodies diluted in 3% (w/v) BSA/1 × PBS. The primary
antibodies were the same as those used for immunoblotting. The secondary antibodies were
Alexa Fluor 568 Donkey Anti-Rabbit IgG or Alexa Fluor 568 Donkey Anti-Mouse IgG
(Life Technologies, A10042 and A10037, respectively). The nuclei were visualized with
4′,6-diamidino-2-phenylindole (DAPI). The coverslips were mounted on glass slides with
Vectashield Mounting Medium (Vector Laboratories, H-1000-10). Confocal microscopic
images were acquired using a Nikon A1 confocal microscope with a 60 × objective.

2.8

Patient Skin Fibroblast Culture
Human skin fibroblasts were prepared and maintained as previously described (89).

Briefly, a skin punch was obtained from consenting patients with symptomatic ALS and
family members free of disease. Brief information on the subjects is shown below. The
biopsies were washed in phosphate-buffered saline (PBS), minced, and incubated in
fibroblast growth media (MEM [Sigma-Aldrich, M5650]) supplemented with 20% FBS, 2
mM L-glutamine, 100 unit/mL penicillin, and 100 μg/mL streptomycin) at 37°C under 5%
27

3 CO2/95% air. Informed consent was obtained from all participants who donated a skin
biopsy. Information on the 11 subjects (five patients with familial ALS with the R521G
mutation, one patient with the P525R mutation, and five healthy controls with WT FUS)
is shown in Table 2.1. The study was approved by the Institutional Review Board of the
University of Kentucky.

2.9

Membrane Filtration
N2a cells were transfected with 3X FLAG FUS construct. After 48 hours, the cells

were lysed in either RIPA buffer (Millipore, 20-188) or a hypotonic lysis buffer (20 mM
HEPES (pH 7.4), 2 mM EGTA, 2 mM MgCl2: Cold Spring Harbor Laboratory). The
lysates were centrifuged at 20,000xg and the supernatant removed. The protein
concentrations were measured. Hydrophilic PVDF membranes (ThermoFisher, 88518)
were applied to the BioRad Dot Blot Filtration Manifold (1706545) and the wells were
rinsed with ACN. 100ug of protein lysate was applied to each well and vacuum pressure
was applied. The wells were washed with lysis buffer three times and the membrane
removed for either western blotting using anti-FLAG antibody (Sigma-Aldrich, A8592) or
mass spectrometric analysis.

2.10 Native Gel Electrophoresis
Cells were harvested with RPIA or hypotonic low detergent lysis buffer and
homogenized by either passing through a 23-gauge needle. Cell lysates were centrifuged
at 20,000 × g at 4 °C for 10 min. The supernatant (50 μL) was taken out and mixed with
10 μL 6× loading buffer (350 mM Tris·Cl, pH 6.8, 30% (vol/vol) glycerol, 0.24% SDS,
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0.02% bromophenol blue). Samples were loaded on a 6% (wt/vol) polyacrylamide gel
soaked in detergent-free running buffer (25 mM Tris, 192 mM glycine). A total of 75 V
was applied for stacking and 120 V was applied for separating. Subsequently, the gel was
incubated with transfer buffer (25 mM Tris, 192 mM glycine, 10% (vol/vol) methanol)
supplemented with 0.25% 5 SDS at 70 °C for 10 min. After the denaturation step, the gel
was ready for transferring and Western blotting following the same procedure as described
earlier.

2.11 Proteomic identification of proteins captured by membrane filtration
The membrane dots were subjected to trypsin digestion and the resulting tryptic
peptides were subjected to liquid chromatography-tandem mass spectrometry (LCMS/MS) as previously described in (2.V). False discovery rate of 1% was used in decoy
search for the high-confidence peptides. Proteins were considered significant
identifications if they met the following criteria: 1) the proteins had at least one unique
peptide; 2) the identified protein had a score above 36; 3) they were unique in any of the
samples.

2.12 Enrichment Analysis of roteins captured by membrane filtration
Proteins identified in FUS inclusions were subjected to functional enrichment
analysis using an integrative online enrichment analysis tool Enrichr (90, 91) that allows
the examination of protein lists using a variety of libraries. Using the mouse exome as the
universe for the enrichment, proteins were analyzed based on their function using the GO:
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Molecular Function database (92, 93) and their disease relevance using the DISEASES
database (94).

2.13 RNA FISH
N2a cells or primary neurons were transfected with EGFP-C3 FUS constructs and
fixed with 4% w/v paraformaldehyde (Pierce, 28908) 48 hours post transfection. Cells were
then permeabilized with 0.25% (v/v) Triton X-100 in 2x saline-sodium citrate (SSC) buffer
(Invitrogen, AM9763) and blocked in Salmon sperm DNA in 2X SSC for one hour. Slides
were incubated with 1ug/uL stock diluted 1:1000 oligo d(T)21 or anti-FUS (exon 4) probe
for one hour at 37°C and then washed three times with 4x SSC and 3x with 2x SSC. The
anti-FUS probe was generated by amplifying FUS exon 4 mRNA and was inserted into a
pCRII-TOPO vector (ThermoFisher, 452640) for in vitro transcription. The anti-FUS
probe was made using ThermoFisher FISH Tag RNA Multicolor Kit nuclei (ThermoFisher,
F32956). Nuclei were visualized using DAPI. Coverslips were mounted on glass slides
using Vectashied Mounting Media (Vector Laboratories, H-1000-10) and confocal images
were acquired using a Nikon A1 confocal microscope.

2.14 RNA Immunoprecipitation followed by qPCR
To measure mRNA bound with protein of interest, immunoprecipitation was
performed as described above. One difference is that SUPERaseIn (ThermoScientific;
AM2696) was included in the RIPA buffer along with protease inhibitors. After
immunoprecipitation, the bead slurry was split into two aliquots. One was for protein
elution and immunoblotting as described above. The other was transferred to a new tube
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for RNA isolation using Trizol reagent per manufacturer instructions. Equal amounts of
isolated RNA were used for cDNA synthesis using the SuperScript III First Strand
Synthesis System (ThermoScientific; 18080051). qPCR was performed using SYBR Green
(ThermoScientific; 4309155) and quantitative results were obtained using the ∆∆CT
method. Primers used in this study are listed in Table 2.2.

2.15 Protein Translation Assays
For the Cap-dependent translation reporter assay: Protein translation efficiency was
measured using a cap-dependent translation reporter assay as previously described (84).
Briefly, N2a cells were transfected with the reporter plasmid along with empty vector, WT
or mutant FUS. After 48 hours, cells were harvested and lysed followed with luminescence
measurement using the Promega luciferase assay kit (Promega, E2940). The cap-dependent
Renilla luciferase activity was compared to that with empty vector. The Firefly luciferase
activity was used as a transfection control.
For the 35S-Met incorporation assay: N2a cells were transfected with 3X FLAG
FUS and after 48 hours incubated with 1µM puromycin (P8833, Sigma) for thirty minutes.
Cells were washed with PBS to remove residual puromycin. Cells were lysed using 1x
RIPA buffer and centrifuged at 1,000xg. Lysates where then run on an SDS-PAGE gel and
transferred to a nitrocellulose membrane for western blotting with anti-puromycin antibody
(Millipore, MABE343). Puromycin staining in lanes was measured using Bio-Rad imaging
software and normalized to actin.
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For the SUnSET Assay: N2a cells were transfected with 3X FLAG FUS and after
48 hours and lysed in water. Lysates were syringe homogenized and centrifuged at 1,000xg
to remove cellular debris. Lysate was then incubated with rabbit reticulocyte lysate, ATP,
and 35SMethionine. The mixture was incubated at 37°C for one hour. We then precipitated
the protein to remove excess 35S-Methionine and took the beta particle count on the
scintillation counter.

2.16 7’ Methyl-guanosine Pulldown
N2a cells were transfected with 3X FLAG FUS and after 48 hours, lysed using 1x
RIPA buffer. The lysate was spun at 1,000xg and precleared using Sepharose beads
(Sigma-Aldrich, CL4B200). After preclearing, the lysates were incubated with 7’ Methylguanosine residues conjugated to agarose beads and incubated at 4°C overnight
(JenaBiosciences, AC-155S). Beads were washed three times and the bound proteins were
eluted by boiling with Laemmli sample buffer (Bio-Rad, 161-0737). Eluates were run on
SDSPAGE gels.

2.17 Bromouridine Immunoprecipitation
N2a cells were transfected with 3X FLAG FUS and after 24 hours incubated with
1µM bromouridine (BrU) (Sigma Aldrich, 850187) for 24 hours. Cells were washed with
PBS to remove residual BrU. Protein and RNA were crosslinked using a StrataLink
Crosslinker (254nm, 1200kJ). Cells were lysed using 1x RIPA buffer and centrifuged at
1,000xg.

Crosslinked

lysate

was

incubated

with

anti-bromodeoxyuridine

to

immunoprecipitate RNA and Protein G UltraLink Resin (Thermo Scientific Pierce, 53126)
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overnight at 4°C. Beads were washed three times and the bound proteins were eluted by
boiling with Laemmli sample buffer (Bio-Rad, 161-0737). Eluates were run on SDS-PAGE
gels followed by immunoblotting.

2.18 NMD Activity Assays
For the NMD Reporter Assay: N2a cells are co-transfected with 3X FLAG FUS
and pcDNA NMD reporter (β-globin WT, β-globin PTC39, GPX-1 WT, GPX-1 PTC) that
were previously reported (10). Cells were harvested 48 hours after transfection and RNA
was extracted using Trizol, purified of plasmid using RQ1 RNase free DNase (Promega,
M6101), purified again using a phenol/chlorophorm method, and subjected to qPCR.
For the Endogenous NMD substrate qPCR: Trizol reagent was used to isolate RNA
from N2a cells or fibroblasts per manufacturer instructions. Equal amounts of isolated
RNA were used for cDNA synthesis using the SuperScript III First Strand Synthesis
System (ThermoScientific; 18080051). qPCR was performed using SYBR Green
(ThermoScientific; 4309155) and quantitative results were obtained using the ∆∆CT
method.

2.19 RNA Stability Assay
N2a cells were transfected with 3x FLAG FUS constructs. After 48 hours, cells
were treated with 1 µM ActinomycinD (Sigma-Aldrich; A1410) for two or four hours, or
DMSO for four hours for experiments examining UPF1, UPF3b, and UPF3a stability. The
same concentration of ActinomycinD was used for examining the stability of ATF3, ATF4,
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TBL2, and CyclophilinD, but a time course of one, two, or three hours, or three hours with
DMSO was used. RNA was isolated using Trizol as described above and subject to qPCR.

2.20 Statistics
Western blot band and lane quantification was done using BioRad Imaging
Software. In assays using patient fibroblasts, mutant band intensity ratios were pooled into
one group. ANOVA with post hoc Tukey HSD (honest significant difference) test was used
to determine p values for multiple pair-wise comparisons. Student’s t test (two-tailed
distribution, two-sample unequal variance) was used to determine p values for simple pairwise comparison. Authors were not blinded to control or experimental groups. All
experiments, except immunofluorescent assay, were done in triplicate.
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Table 2.1 Patient Fibroblasts
ID Group

ID Group

FUS
Genotype

Gender

Age at Biopsy

017
010
012
008
089
091
001
014
007
018
090

Control
Control
Control
Control
Control
ALS
ALS
ALS
ALS
ALS
ALS

WT
WT
WT
WT
WT
R521G
R521G
R521G
R521G
R521G
P525R

F
F
F
F
M
F
M
M
M
F
F

43
36
63
24
20
31
56
42
58
40
26
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Table 2.2 List of qPCR Primers
GENE

FORWARD

REVERSE

MOUSE UPF1

AGAGCAGCCTGAAGGACATC

TCCAGCTTGTTGATCTGCTG

MOUSE

GAGTGACCCTGTTTACGCC

TCAAAGTGGGAGGTAATCTTCG

ATGCGCTCGGAAGAGG

CTACTGGGCCTTGTGTCC

CCAGGGATATGGTTCCACTG

CTGCTAGGAGCTGGCTGTTG

ATAAACACCTCTGCCATCGG

GCCTCCTTTTCCTCTCATCTTC

GGTTCTCCAGCGACAAGG

GCATCGAAGTCAAACTCTTTCAG

TCCACGATCAACACTAACCAG

CGAAACAGACCTCCCAGAC

CCCTCCAACTCCAAGAACC

TTCTCCTGTACACAACGCAC

CTGTGAAGGCATCAACATTTCTG

GACCACCATCCGCTTTTTCTT

UPF3B
MOUSE
UPF3A
MOUSE FUS
(EXON 4)
MOUSE
ATF3
MOUSE
ATF4
MOUSE
TBL2
MOUSE
CYCLOPHIIN
D
MOUSE
RPL13A
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HUMAN

AGAGCAGCCTCAAGGACATC

TCCAGCTTGTTGATCTGCTG

GTTCATATTCCCGTTCCCTCTC

TGCCCAAGCGTTCTGATAG

TCCAGCTTGTTGATCTGCTG

GGCAATCTTCTGGAATGGAG

GTTTGCCATCCAGAACAAGC

GTCGCCTCTTTTTCCTTTCATC

CCAAGCACTTCAAACCTCATG

ATCCATTTTCTCCAACATCCAATC

AATATCAGCGGATTCGGAAGG

ACAGGTAGCCAGGTATTTGC

AGAGCTACGAGCTGCCTGAC

GGATGTCCACGTCACACTTC

AGGAGAAGTCTGCCGTTACT

GAGCCAGGCCATCACTAAAG

GGGACTACACCGAAATGAATGA

GGACAGCAGGGCTTCTATATC

UPF1
HUMAN
UPF3B
HUMAN
UPF3A
HUMAN
ATF3
HUMAN
ATF4
HUMAN
TBL2
HUMAN

B-

ACTIN
NMD
REPORTER:
HUMAN

B-

GLOBIN
NMD
REPORTER:
RAT GPX-1
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CHAPTER 3. PROTEOMIC ANALYSIS OF FUS INTERACTING PROTEINS PROVIDES INSIGHTS
INTO FUS FUNCTION AND ITS ROLE IN ALS
Modified from the manuscript “Proteomic analysis of FUS interacting proteins provides
insights into FUS function and its role in ALS”, published in the Biochimica et
biophysica acta. 2016;1862(10):2004-14. Epub 2016/07/28. doi:
10.1016/j.bbadis.2016.07.015. PubMed PMID: 27460707; PMCID: PMC5055831. The
introduction was simplified for fluidity and experiments not performed by M.K were
excluded.

3.1

Introduction
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a

progressive and ultimately fatal neurodegenerative disease of the upper and lower motor
neurons of the brain and spinal cord. At any given time, approximately 30,000 people in
the United States are living with the disease (95). There is currently no cure available for
those afflicted (96). General symptoms of ALS are muscle weakness and wasting triggered
by the degeneration of motor neurons. In order to develop effective preventive measures
or cures, we have to gain a better understanding of the molecular etiology of the disease.
Approximately 10% of the ALS cases are familial (fALS) and caused by heritable
mutations in a number of different genes. A subset of fALS cases is caused by autosomal
dominant mutations in the gene encoding Fused in Sarcoma/Translocated in Liposarcoma
(FUS/TLS) (2, 3). FUS mutations were also identified in a subset of the sporadic ALS
(sALS) cases (97-99). In most tissues, FUS is predominantly localized to the nucleus with
a notable cytoplasmic presence in neurons (100). FUS has several known functions in
38

multiple cellular pathways. FUS binds RNA and shuttles between the nucleus and the
cytoplasm, participating in nucleo-cytoplasmic RNA shuttling (101). FUS also plays roles
in DNA repair (102-104), transcription (13, 20, 33, 61, 105-111), RNA splicing (20, 112,
113), dendritic RNA transport (114-116), and miRNA biogenesis and function (78, 117).
However, the physiological functions of FUS are still not fully understood. The ALSrelated FUS mutations cause varied degrees of cytoplasmic mis-localization of FUS and
the formation of stress granule-like structures (12, 62, 63, 72). In a subset of frontotemporal
dementia cases, pathological cytoplasmic mis-localization of FUS was found without FUS
mutations (118, 119). The depletion of FUS in the nucleus likely results in partial loss of
its nuclear function(s). In addition, its cytoplasmic accumulation and the formation of stress
granule-like structures and other ribonucleoprotein complexes might lead to a gained
toxicity

phenotype.

These

loss-of-function

and

gain-of-function/gain-of-toxicity

mechanisms are both plausible and are not mutually exclusive (40, 120).
To gain insight into the normal functions of FUS and the pathogenesis caused by
its mutations, we performed GST-FUS pull-downs from human cells expressing wild-type
and R521G mutant FUS, followed by proteomic identification of the FUS interacting
partners. In addition to previously reported interacting proteins, many novel interacting
partners were identified in this study, including members of the spliceosome, IMP1dependent ribonucleoprotein particles, transport RNA granules and stress granules. Many
of the identified interacting partners are shared between two or more of these
ribonucleoprotein particles. We selected a set of the identified FUS interacting partners
that participate in a wide range of functions for further analysis. We validated the
interaction of FUS with the selected partners and determined the RNA dependence of those
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interactions. We found that the interactions of FUS with some partners were enhanced,
whereas with others were partly or completely abrogated by RNase digestion. Importantly,
we found that FUS interacted with hnRNPA1 and Matrin-3, proteins whose mutations were
also identified to cause familial ALS (121, 122). We found that ALS mutants of FUS colocalized with Caprin-1, DDX3X, and DHX9 in cytoplasmic inclusions that could lead to
the mis-regulation of their respective pathways, providing further clues to the mechanism
of ALS pathogenesis.

3.2

Results
Identification of FUS interaction partners

We generated GST-FUS expression constructs using the pEBG vector that
expresses the glutathione S-transferase (GST) gene of Schistosoma japonicum under
control of the human EF-1α promoter (86). We performed GST pull-downs from human
HEK293T (293T) cells transfected with wild-type (WT) or R521G mutant GST-FUS or
the GST vector. The GST-FUS pull-downs were performed both in the presence and
absence of added RNase in the cellular lysates. SDS-PAGE revealed major banding pattern
differences between the GST vector control and the GST-FUS lanes (Fig. 3.1). Proteins
that were identified in the vector lane (several human glutathione S-transferases and other
proteins) and common contaminants such as keratin, heat shock proteins and abundant
cytoskeletal components were excluded from the analysis of the GST-FUS lanes. It is noted
that no endogenous FUS was identified in the GST vector control lane, suggesting that the
endogenous FUS did not bind non-specifically to the Glutathione Sepharose 4B beads.
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We identified the FUS interacting proteins using the Mascot software (Matrix
Science). Mascot uses probability-based scoring to judge whether identifications are
significant. The peptide score shows the probability of whether the observed match is a
random event. Scores are reported as −10 × log10(P), where P is the probability. For
example, a Mascot score of 30 means that the probability of a peptide identification being
a random event is 0.001. The protein score is calculated from the scores of the individual
peptides. A total of 112 proteins were identified as FUS-interacting partners in this study.
Among them, 70 were non-ribosomal proteins (Supplemental Table 3.1) and 42 were
ribosomal proteins (Supplemental Table 3.2). The count of the peptides identified at high
confidence level (false discovery rate < 1% in decoy search) is shown in the tables, and
only proteins identified with a compounded score of 30 or higher are listed. The MS/MS
spectra of high-confidence peptides with scores lower than 50 were manually inspected
and confirmed. Proteins identified with these parameters are considered highly confident
identifications.
Validation and characterization of selected FUS interactions

We demonstrated the co-precipitation of endogenous DHX9, Matrin-3, ILF2 and
hnRNPA1 with endogenous FUS immunoprecipitated from SH-SY5Y cells (Fig. 3.2). We
also validated the interaction of FUS with endogenous DHX9, Matrin-3, DDX3X, Caprin1, ILF2 and hnRNPA1 in 293T cells using GST-FUS pull-down followed by immunoblot
with specific antibodies (Fig. 3.3A–B, lanes 1 and 3). We determined whether the
interactions of FUS with the above proteins depended on RNA. Cells were transfected with
GST vector or GST-tagged WT, R521G or P525L FUS expression constructs and the cell
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lysates were subjected to GST pull-down either with or without the addition of RNase (Fig
3.3A). The precipitation of the baits was verified with anti-GST immunoblot (Fig. 3.3B).
The immunoblots of the co-precipitating proteins were quantified from three independent
experiments (Fig. 3.3C). The binding of FUS to its interaction partners was differentially
affected by RNase treatment (Fig. 3..3A and C). The amounts of the co-precipitated Matrin3 and that of the RNA helicases DHX9 and DDX3X were significantly enhanced by RNase
treatment. The interactions of FUS with Caprin-1 and ILF2 were weakened, but not fully
abrogated, by the RNase treatment. The interaction of FUS with hnRNPA1 was entirely
dependent on RNA, as the RNase treatment completely abolished its interaction with FUS.
Thus, the interactions of FUS with DHX9, Matrin-3 and DDX3X are likely protein-protein
interactions that do not require RNA, whereas the interactions with Caprin-1, ILF2, and
hnRNPA1 are partly or fully RNA-dependent.
Co-localization of FUS interaction partners with cytoplasmic ALS mutant
FUS inclusions

We tested whether the selected interaction partners co-localized with cytoplasmic
inclusions of mutant FUS in the SH-SY5Y human neuroblastoma cell line transfected with
EGFP-tagged WT, R521G or P525L FUS. We found that EGFP-tagged WT FUS localized
to the nuclei of SH-SY5Y cells. The localization of R521G mutant FUS ranged widely
from mostly nuclear to mostly cytoplasmic. The localization of P525L FUS was even
further shifted towards the cytoplasm. Both the R521G and the P525L FUS mutants formed
cytoplasmic inclusions (Fig. 3.4). The DHX9 protein was primarily localized to the nuclei
of SH-SY5Y cells sharing a similar distribution pattern with that of nuclear FUS (Fig.
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3.4A). The expression of both R521G and P525L FUS resulted in the accumulation of
small amounts of DHX9 in cytoplasmic mutant FUS inclusions (Fig. 3.4A). The DDX3X
protein was mostly localized to the cytoplasm (Fig. 3.4B). DDX3X was efficiently
sequestered by the cytoplasmic inclusions of both R521G and P525L mutant FUS (Fig.
3.4B). We had similar observations with the mostly cytoplasmic CAPR1/Caprin-1. The
expression of R521G and P525L FUS induced the formation of cytoplasmic Caprin-1positive inclusions, most of which co-localized with the mutant FUS inclusions (Fig. 3.4C).
We also demonstrated the co-localization of DHX9, DDX3X and Caprin-1 with
cytoplasmic EGFP-P525L mutant FUS inclusions in primary cortical neurons (Fig. 3.5)
The co-localization of DHX9, DDX3X and Caprin-1 with mutant FUS inclusions
was quantified in SH-SY5Y cells transfected with EGFP-tagged P525L mutant FUS in four
independent experiments, each representing over 400 transfected cells. On average, 24.5%
of the transfected cells contained cytoplasmic P525L mutant FUS inclusions. DHX9 colocalized with 89.7%, DDX3X with 97.9%, and Caprin-1 with 88.7% of the cytoplasmic
P525L mutant FUS inclusions, respectively.
The FUS interaction partners Matrin-3 and hnRNPA1 were localized to the nuclei
of SH-SY5Y cells and were not detected in cytoplasmic mutant FUS inclusions (Fig 3.6A–
B). The ILF2 protein was primarily in the nuclei and was not detected in cytoplasmic
mutant FUS inclusions, either (Fig. 3.6C). These results suggest that the detected
complexes of FUS with Matrin-3, hnRNPA1, and ILF2 were likely nuclear that will be
explored in future studies.
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Significantly enriched Gene Ontology (GO) terms among the identified
FUS interacting partners

We searched for significantly enriched GO terms for the identified FUS interacting partners
using the STRING server (http://www.string-db.org/, (123)). The enriched GO Biological
Processes, Molecular Functions and Cellular Components of FUS interacting partners are
summarized in (Tables 3.3- 3.5), respectively. The p-values shown in the tables are
Benjamini-Hochberg corrected p-values for enrichment of the terms in question,
representing the estimated false discovery rate (124).
Based on the GO Biological Processes, the majority of significantly enriched terms
were related to various aspects of gene expression and RNA metabolism, such as
chromosomal organization, transcription, RNA splicing, RNA processing, RNA transport,
translation and RNA stability (Table 3.1). Based on the GO Molecular Functions, the
majority of the identified FUS interaction partners are RNA and/or DNA binding proteins
with a considerable enrichment for RNA helicases (Table 3.2). The FUS interacting
partners CN166, CTR9 and ZN326 represent three of the 21 UniProt entries annotated with
the significantly enriched GO Molecular Function “RNA polymerase II core binding”
(Table 3.2). Among the significantly enriched GO Cellular Components were various
ribonucleoprotein complexes including ribosomes, splicing complexes, the SMN-Sm
protein complex and cytoplasmic stress granules (SGs). Also enriched were chromosomal
proteins and components of extracellular exosomes (Table 3.3).
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FUS interacts with overlapping ribonucleoprotein complexes

Our analysis showed that the majority of the identified non-ribosomal FUS
interaction partners (Supplemental Table 3.1) are known members of at least one of four
types of ribonucleoprotein complexes: spliceosomes, IMP1-dependent ribonucleoprotein
(RNP) granules, transport granules or stress granules (Fig. 3.7). In Fig. 3.7, only the FUSinteracting ribosomal proteins that were specifically identified as part of the above
complexes are shown.
This study identified the following FUS-interacting proteins that were previously
identified

as

spliceosomal

ROA3/hnRNPA3,

components:

HNRPC/hnRNPC,

ROA1/hnRNPA1,

ROA2/hnRNPA2B1,

RBMX/hnRNPG,

HNRH1/hnRNPH,

HNRPK/hnRNPK, HNRPM/hnRNPM, HNRPR/hnRNPR, HNRPU/hnRNPU, PABP1,
RSMB/SNRPB, SMD1, SMD3, RUXE/SNRPE, SF3B1, SF3B3, U520/SNRNP200,
SK2L2, DDX5 and ZCHC8 (125), and SR140 and SRSF7 (126, 127). In addition, FUSinteracting proteins are involved in a tRNA splicing ligase complex that is not part of the
spliceosome: RTCB/HSPC117, CN166/CGI-99 and DDX1 (128).
Another group of FUS interacting proteins identified in this study belong to the
IMP1-dependent

mRNP

granules.

They

include:

DHX9,

HNRPU/hnRNPU,

NUCL/Nucleolin, PABP1, ILF2, ILF3, HNRPR/hnRNPR, PABP4, ROA1/hnRNPA1,
ROA2/hnRNPA2B1, RLA0, RS3, RS3a, RS4X, RS6, RS8 (129), as well as
HNRPK/hnRNPK, ROA3/hnRNPA3, and ELAV1/HuR (130).
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The third group of our identified FUS-interacting proteins contains components of
RNA transporting granules. DDX1, DDX3X, DDX5, RTCB/HSPC117, CN166/CGI-99,
FMR1, FXR1, RL3, ROA1/hnRNPA1, HNRPU/hnRNPU, and NUCL are components of
a FUS-positive kinesin-mediated RNA transporting dendritic granule complex (131).
Moreover, the DHX9, FMR1, HNRPU/hnRNPU, ILF3, NUCL, PABP1, RLA0, RL6,
RL7A, RL10, RL14, RS2, RS3A, RS6, and RS8 proteins identified in this study were
reported

as

complexes (132,

components
133).

In

of

Staufen-containing

addition,

transport

ribonucleoprotein

ROA2/hnRNPA2 (134) and

CAPR1/Caprin-

1 (74) were also identified in RNA transport granules.
The fourth group among our identified FUS-interacting proteins belongs to stress
granules.

They

DHX36/RHAU,

include

ATX2L,

ELAV1/HuR,

CAPR1/Caprin-1,
FMR1,

FXR1,

DDX1,
G3BP2,

DDX3X,

DDX6,

ROA1/hnRNPA1,

ROA2/hnRNPA2, HNRPK/hnRNPK, ILF3, PABP1, RS3, RS6, RS18, RBP56/TAF15 and
PABP4 (73, 135). Moreover, the two FUS-interacting proteins DDX6/RCK and MOV10
are components of processing bodies (P-bodies) (136-138) that functionally interact with
stress granules (139). NPM, PARP1 and NUCL were identified as part of the SWAP
complex, a B-cell-specific DNA recombination complex (140).
NPM, PARP1 and NUCL were identified as part of the SWAP complex, a B-cellspecific DNA recombination complex (140).
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3.3

Discussion
Identification and validation of FUS interaction partners

We identified 70 non-ribosomal and 42 ribosomal proteins as FUS interaction
partners in this study (Fig. 3.1 and Fig. 3.6). No endogenous FUS was identified in the
GST vector control pull-down. Proteins identified in the GST vector control experiment
were excluded from the analysis of the GST-FUS pull-downs. Most FUS interaction
partners we identified are known RNA and DNA binding proteins (Table 3.1) involved in
pathways regulating various aspects of gene expression and RNA metabolism including
transcription, splicing, RNA processing, RNA stability, RNA transport and translation
(Table 3.1). Selected interactions were validated by immunoprecipitation and GST pulldown followed by immunoblotting (Fig. 3.2, Fig. 3.3). Immunostaining followed by
confocal microscopy showed that the FUS interaction partners DHX9, DDX3X and
Caprin-1 localized to cytoplasmic FUS inclusions (Fig. 3.4, Fig. 3.5).
Our method to generate cellular lysates efficiently extracted not only cytosolic
proteins but also predominantly nuclear proteins such as WT FUS, DHX9, Matrin-3 and
hnRNPA1 (Fig. 3.2, Fig. 3.3, Fig. 3.4, Fig. 3.5, and Fig 3.6). In the pull-down studies, we
detected interactions between proteins mostly residing in different cellular compartments
such as the interactions between the predominantly nuclear WT FUS and the almost
exclusively cytoplasmic DDX3X or Caprin-1 (Fig. 3.3, Fig. 3.4, Fig. 3.5). This observation
demonstrates the significance of examining interacting proteins with imaging techniques
in cells to determine whether the proteins interact with each other in live cells under
physiological conditions.
47

Many FUS interacting partners participate in two or more of the ribonucleoprotein
complexes shown in Fig. 3.7. Ribonucleoprotein complexes are highly dynamic structures
that can exchange components and transition from one kind of complex to another. It is
conceivable that FUS cycles between different molecular complexes and ribonucleoprotein
granules depending on a number of cellular influences including subcellular localization
and stress conditions.
The RNA dependence of FUS interactions

The identified interactions were differentially impacted by the introduction of
RNase into the pull-down mixtures. Whereas the interactions of FUS with DHX9, Matrin3 and DDX3X are likely protein-protein interactions that were enhanced by RNase
digestion, the interactions of FUS with CAPR1, ILF2, and hnRNPA1 were partly or fully
RNA-dependent (Fig. 3.3). It is likely that FUS molecules cycle between RNA-bound and
RNA-unbound states as they interact with successive target RNA molecules. Our results
showed that FUS displayed differential affinities to its protein interacting partners in the
RNA bound and RNA-unbound states, suggesting that the protein interacting partners of
FUS likely also change during the RNA binding cycles. RNase treatment can free up
molecular surfaces for protein-protein interactions otherwise occupied by RNA.
Alternatively, the RNA-bound and unbound states of FUS might assume different
conformations, regulating the preference of FUS to varied interaction partners.
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The interaction of FUS with the ALS-related proteins Matrin-3 and
hnRNPA1

We discovered that FUS interacted with MATR3/Matrin-3 and ROA1/hnRNPA1
(Figs. 3.2, 3.3 and Supplemental Table 3.1), proteins whose mutations were also identified
to cause familial ALS (121, 122). This suggests that FUS might be involved in common
pathogenic pathways with Matrin-3 and hnRNPA1. There are intriguing differences
between these complexes, though. The interaction between FUS and Matrin-3 was
enhanced by RNase treatment, whereas the FUS-hnRNPA1 interaction was entirely
dependent on RNA (Fig. 3.3). It is relevant that hnRNPA1 was reported to localize to stress
granules (121, 141) similarly to FUS (10, 12, 62, 63, 72, 100, 142). The analysis of the role
of the FUS-Matrin-3 and FUS-hnRNPA1 complexes in ALS pathogenesis is underway.
FUS interacts with regulators of protein phosphorylation

We identified the FUS interaction partners KHDR1, ILF2, ILF3 and RBMX/
hnRNPG that were previously reported to be in a complex with the serine/threonine-protein
phosphatase PP1-α catalytic subunit PP1A (Fig. 3.7) (143). The ILF2 and ILF3 proteins
were also reported to interact with and regulate the DNA-dependent protein kinase (DNAPK) (144). The phosphorylation of FUS by DNA-PK was recently reported (145). Our
results suggest that the KHDR1/ILF2/ ILF3/RBMX complex might regulate FUS
phosphorylation. FUS also interacted with CSK21, the catalytic alpha subunit of casein
kinase II and the serine/threonine-protein kinase Nek10. The casein kinase II-mediated
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FUS phosphorylation and its functional relevance are currently being investigated in our
laboratory.
Loss of nuclear FUS functions due to ALS mutations

We found that FUS interacted with numerous proteins that regulate nuclear
processes. Twenty-six of the FUS interacting partners we isolated were annotated as
regulators of DNA-templated transcription (Table 3.1). Twenty-three of the FUS
interaction partners we identified are known spliceosomal components (Table 3.1, Fig 3.7).
The splicing-related “Survival motor neuron” (SMN)-Sm protein complex was also among
the significantly enriched GO Cellular Components (Table 3.3). Additionally, the FUS
interacting partners RTCB, CN166 and DDX1 are components of a tRNA splicing ligase
complex that is not part of the spliceosome (Fig 3.8) (128). Although we did not identify
FA98B/FAM98B, a fourth component of the tRNA splicing ligase complex as a FUS
interacting partner, we did identify its closest human homolog, FA98A/FAM98A
(Supplemental Table 3.1). The FUS-interacting RTCB/CN166/DDX1 complex was also
reported to play a role in nucleo-cytoplasmic RNA shuttling (146), a function shared by
FUS (101), suggesting potential functional co-operation. The familial ALS-related FUS
mutations cause cytoplasmic mis-localization of FUS (2, 3, 12, 62, 63, 72). It is
conceivable that the resulting lower nuclear FUS level leads to depletion of its nuclear
complexes and loss of its nuclear functions.
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Mis-regulation of cytoplasmic processes by ALS mutant FUS

We identified 34 FUS interacting partners that are known components of either
IMP1-dependent RNP granules, RNA transport granules, or both (Fig 3.8). IMP1, also
called insulin-like growth factor 2 mRNA-binding protein 1 is an RNA binding protein that
recruits target mRNAs to cytoplasmic protein-RNA complexes. IMP1 stabilizes the
recruited mRNAs allowing their storage and transport and modulates the location at which
the target mRNAs are translated (130, 147-149). IMP1 plays a direct role in the transport
and translation of transcripts required for axonal regeneration (150). The IMP1-dependent
RNP granules are distinct from RNA transport granules and stress granules (129), although
they share components (Fig 3.7). The ALS-related FUS mutations cause the formation of
FUS-positive cytoplasmic inclusions (12, 62, 63, 72) that sequestered the IMP1-dependent
RNP granule and/or transport granule components DHX9, DDX3X, and CAPR1 (Fig.
3.4, Fig. 3.5, Fig 3.7). The sequestration of these FUS interacting partners could lead to
loss of their function in RNA transport and localized translation. Because of the extreme
proportions of motor neurons, they rely on mRNA transport and localized translation more
than other cell types. Accordingly, motor neurons could be especially sensitive to the
sequestration of mRNA transport granule components.
We identified 21 reported stress granule (SG) components as FUS interacting
partners (Fig. 3.7). We found that the cytoplasmic ALS mutant FUS inclusions were
immunopositive for the SG components DDX3X and CAPR1 (Fig. 3.4, Fig. 3.5, Fig. 3.7).
We previously reported that the mutant FUS inclusions were also immunopositive for
another SG component, PABP1 (72). Stress granules are stress-induced ribonucleoprotein
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complexes in eukaryotic cells that contain translationally silent pre-initiation complexes
and a host of RNA-binding proteins (73, 151). Two of the FUS interacting proteins we
identified were processing body or P-body components (Fig. 3.7). P-bodies are discrete
cytoplasmic foci where mRNA degradation takes place (152). P-bodies functionally
interact with stress granules (139). Among normal conditions, stress granules exist for up
to a few hours. The normal dynamics of stress granules is critical for the survival of stressed
neurons (73). The perturbation of stress granule dynamics might be a pathological process
of central importance in ALS (138, 153, 154). Accordingly, triggering the formation of
unusually stable stress granule-like structures by mutant FUS and the resulting perturbation
of stress granule dynamics might cause a gained toxicity phenotype.
During the revision of this manuscript, a comparative interactomics study of varied
ALS-associated proteins was published that identified a partially overlapping set of FUS
interacting partners (155).

3.4

Conclusions
In summary, our results demonstrate that the FUS interacting partners participate

in multiple pathways, providing insights into the physiological functions of FUS as well as
the potential mis-regulation of these pathways by ALS mutant FUS. Among the pathways,
mRNA transport and stress granule dynamics are particularly important for the health of
motor neurons. Mis-regulation of the dendritic and/or axonal mRNA transport and the
generation of abnormally stable ectopic stress granule-like structures by ALS mutant FUS
are likely contributors to ALS pathogenesis.
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Table 3.1 Selected enriched GO Biological Processes among the identified FUS interacting
partners.
The corresponding p-values and the numbers of FUS interaction partners are shown
without/with the inclusion of ribosomal FUS interaction partners in the search.
Number of FUS
interaction partners

Term

p-Value

RNA processing

1.659e −32/3.050e −36 37/46

RNA splicing

4.750e −27/2.960e −22 27/27

mRNA processing

9.890e −27/1.499e −21 28/28

mRNA metabolic process

1.149e −25/6.829e −73 30/67

mRNA splicing, via spliceosome

1.149e −25/1.760e −21 23/23

Gene expression

1.220e −18/3.089e −33 49/80

Posttranscriptional regulation of 6.050e −13/1.650e −13 17/20
gene expression
mRNA stabilization

2.940e −7/1.150e −6

6/6

Regulation of translation

8.299e −7/3.019e −8

11/14

RNA localization

1.980e −5/2.180e −4

8/8

Transcription, DNA-templated

6.779e −5/4.710e −2

25/26

mRNA 3′-end processing

3.570e −4/1.649e −3

5/5

via 8.429e −4/1.699e −3
and

3/3

tRNA
splicing,
endonucleolytic cleavage
ligation
ncRNA metabolic process

1.000e −3/3.459e −10

9/18

Termination of RNA polymerase 2.360e −3/8.259e −3
II transcription

4/4

Transcription
from
polymerase II promoter

RNA 5.130e −3/1.499e −1

11/11

1.149e −2/2.939e −1

11/11

Chromosome organization
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Table 3.2 Selected enriched GO Molecular Functions among the identified FUS interacting
partners.
The corresponding p-values and the numbers of FUS interaction partners are shown
without/with the inclusion of ribosomal FUS interaction partners in the search.
Number
of
FUS
interaction partners

Term

p-Value

RNA binding

5.000e −43/6.379e −74 53/87

Single-stranded
binding

RNA

ATP-dependent
helicase activity

RNA

Double-stranded
binding

RNA

2.070e −10/9.300e −9

9/9

2.220e −10/1.099e −8

9/9

8.889e −6/1.289e −4

6/6

mRNA 3′-UTR binding

4.350e −5/4.180e −4

5/5

DNA binding

3.330e −4/2.750e −2

22/25

RNA polymerase II core
1.690e −3/7.629e −3
binding

3/3

1.359e −2/5.000e −4

2/3

mRNA 5′-UTR binding
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Table 3.3 Selected enriched GO Cellular Components among the identified FUS
interacting partners.

Term

p-Value

Number of FUS interaction
partners

Ribonucleoprotein complex 2.369e −68 66
Ribosome

1.769e −46 38

Spliceosomal complex

1.080e −20 20

Ribonucleoprotein granule

3.200e −16 16

Cytoplasmic stress granule

3.430e −10 8

Extracellular exosome

1.430e −9

42

tRNA-splicing
complex

1.919e −6

4

SMN-Sm protein complex

5.140e −5

4

Chromosome

2.449e −3

13

ligase
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Figure 3.1
The identification of FUS interaction partners. GST pull-downs were performed from
cellular extracts of 293T cells transfected with the indicated GST expression constructs.
RNase was included in the cellular lysates as indicated. The pull-down mixtures were
subjected to SDS-PAGE on 4–15% gradient gel, followed by Sypro Ruby staining. Vec,
vector. The molecular weights of marker bands are shown on the left (kDa).
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Figure 3.2
Verification

of

selected

FUS

interacting

partners

with

endogenous

FUS

immunoprecipitation. Immunoprecipitations were performed from cellular extracts of SHSY5Y cells with a FUS-specific and a control (HA) antibody. The immunoprecipitates
were subjected to SDS-PAGE followed by immunoblot with the indicated antibodies. IP,
immunoprecipitation; Ext, extract; IB, immunoblot. The molecular weights of nearby
marker bands are shown on the left (kDa).
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Figure 3.3
Verification of selected FUS interacting partners with GST-FUS pulldown. (A–B) GST
pull-downs were performed from cellular extracts of 293T cells transfected with the
indicated GST expression constructs. RNase was included in the cellular lysates as
indicated. The pull-down mixtures were subjected to SDS-PAGE followed by immunoblot
with the indicated antibodies. PD, pull-down; Ext, extract; Vec, vector; RG, R521G; PL,
P525L; IB, immunoblot. The molecular weights of nearby marker bands are shown on the
left (kDa). (C) Quantification of the RNA dependence of the FUS interactions shown in
panel A. The band intensities from three independent experiments were quantified and
normalized to the respective band with no RNase added. The error bars stand for standard
deviation. Statistical significance was determined with Student's t-test. *: 0.01 < p < 0.05;
**: 0.001 < p < 0.01; ***: p < 0.001.
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Figure 3.4
The co-localization of DHX9, DDX3X and Caprin-1 with ALS mutant FUS inclusions in
SH-SY5Y cells. Confocal microscopic images of EGFP-tagged FUS (WT, R521G or
P525L) fluorescence and DHX9 (A), DDX3X (B) and Caprin-1 (C) immunofluorescence
in SH-SY5Y cells. The co-localization of mutant FUS and DHX9 in cytoplasmic inclusions
is shown by arrows in (A). Scale bars, 10 μm.
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Figure 3.5
The co-localization of DHX9, DDX3X and Caprin-1 with ALS mutant FUS inclusions in
primary cortical neurons. Confocal microscopic images of EGFP-tagged WT and P525L
mutant FUS fluorescence and DHX9 (A), DDX3X (B) and Caprin-1 (C)
immunofluorescence in cultured mouse primary cortical neurons. The boxed areas are
magnified in the respective panels on the right. The co-localization of mutant FUS with the
respective interaction partners in cytoplasmic inclusions is shown by arrows. Scale bars,
50 μm.
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Figure 3.6
The Matrin-3, hnRNPA1 and ILF2 proteins do not localize to ALS mutant FUS inclusions
in SH-SY5Y cells. Confocal microscopic images of EGFP-tagged FUS (WT, R521G or
P525L) fluorescence and Matrin-3 (A), hnRNPA1 (B) and ILF2 (C) immunofluorescence
in SH-SY5Y cells. Scale bars, 10 μm.
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Figure 3.7
FUS interacts with overlapping ribonucleoprotein complexes. Venn diagram of a subset of
the identified FUS interacting partners. Venn diagram of a subset of the identified FUS
interacting

partners. The

background

diagram was

obtained

from

Commons, https://commons.wikimedia.org/wiki/File:4-way-venn_vector.svg
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Wikimedia

CHAPTER 4. ALS MUTATIONS OF FUS SUPPRESS PROTEIN TRANSLATION AND DISRUPT
THE REGULATION OF NONSENSE-MEDIATED DECAY
Modified from the manuscript “ALS mutations of FUS suppress protein translation and
disrupt the regulation of nonsense-mediated decay”, published in PNAS. 2018. Epub
2018/11/21. doi: 10.1073/pnas.1810413115. PubMed PMID: 30455313. The introduction
was simplified for fluidity.

4.1

Introduction
FUS is a DNA- and RNA-binding protein that is primarily localized to the nucleus,

where it forms dynamic ribonucleoprotein granules. In contrast, ALS-related mutant FUS
accumulates in the cytoplasm and forms stable ribonucleoprotein granules, which can lead
to inclusion bodies and potentially contribute to neurotoxicity (2, 3, 156). FUS mutations
have also been shown to impact many RNA metabolic processes, including transcription
(9, 13, 20, 22), splicing (37-39), mRNA transport (131), and stabilization (68), ultimately
contributing to neuronal dysfunction. Recent studies demonstrated that mutations in FUS
cause the liquid–liquid phase separation (LLPS) of FUS protein and the formation of selfassembled hydrogels or liquid droplets in vitro (8, 157). It is noted that LLPS has also been
reported for other RNA metabolic proteins involved in ALS, including TDP-43 (158),
C9ORF72 dipeptide repeat (159), hnRNPA1 (158), and TIA1 (70). Thus, other cellular
proteins are likely to be included in granules during LLPS in living cells, but the identities
of such proteins remain to be determined.
This study started with testing the hypothesis that the identification of proteins
associated with mutant FUS-dependent cytoplasmic granules is likely to provide critical
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insights into the toxic mechanism of mutant FUS. We developed a protocol to capture the
dynamic mutant FUS-positive granules (22, 156) by membrane filtration and identified
protein components by proteomic approaches. The bioinformatics analysis of proteins
identified in wild-type (WT) and mutant FUS granules revealed multiple RNA metabolism
pathways, among which protein translation and mRNA surveillance appeared to be novel.
We thus hypothesize that mutant FUS plays a role in protein translation. Two
previous studies reported that ALS-linked FUS mutations were recruited to
ribonucleoprotein granules; thus, FUS was speculated to be involved in protein translation
(66, 156). However, protein translation was not measured in either study. Using three
independent assays, we found that mutant FUS indeed impaired protein translation and that
the cytoplasmic inclusions of mutant FUS were positive for stalled ribosomal complexes.
Mutations in FUS have been demonstrated to cause aberrant splicing (160);
however, the molecular mechanism by which cells handle defective mRNA has not been
explored in ALS. Nonsense-mediated decay (NMD) is a major mRNA surveillance system
that is known to degrade defective mRNA and ∼3– 20% of all mRNAs (161). NMD and

protein translation are interrelated, as NMD utilizes the translocating ribosome as a
proofreading mechanism for sensing defective mRNAs (162-164). We demonstrate that
the phosphorylation level of a critical NMD regulator UPF1 (163), the NMD complex

assembly, and theUPF1-mRNA binding all increased in the presence of mutant FUS,
supporting that NMD is activated by mutant FUS. Additionally, two potent NMDactivating regulators UPF1 and UPF3b (163, 165, 166) were up-regulated, while the
negative NMD regulator UPF3a (167) was down-regulated in skin fibroblast cells derived
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from a cohort of patients with ALS with FUS mutations compared with cells from control
subjects, indicating disruption of the autoregulation of NMD. The hyperactivation of NMD
was demonstrated using an NMD reporter assay in N2a cells and measuring endogenous
mRNAs in the fibroblast cells of FUS ALS cases. Overall, the findings from this study thus
provide an in-depth understanding of how RNA metabolism and protein translation are
impacted by mutations in FUS and produce insights into the disease-causing mechanism
of the mutant FUS subtype of ALS.

4.2

Results
Proteins related to translation and mRNA surveillance are enriched in
mutant FUS inclusions.

A more complete understanding of the protein composition that makes up the
inclusions characteristic of mutant FUS-dependent ALS would provide a better
understanding of the mechanism(s) driving the disease. To achieve this, we adapted a
membrane filtration assay that was originally developed for detecting differentially soluble
protein complexes (168). Utilizing previously described conditions in which
radioimmunoprecipitation assay (RIPA) buffer was used to lyse cells (169), none of the
WT, R495X, P525L, or R521G mutant FUS proteins were detected on the PVDF
membrane (Fig. 4.1A). As a positive control and negative control, respectively, A4V
mutant SOD1 was detected on the PVDF membrane filter, while WT SOD1 was not. The
results suggest that, unlike A4V mutant SOD1-dependent cytoplasmic aggregates, mutant
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FUS cytoplasmic inclusions are dynamic and disassembled under the experimental
conditions.
A protocol using a hypotonic lysis buffer with a low detergent concentration was
developed (Fig. 4.2A). Using these conditions, P525L and R495X mutant FUS was
detected on the membrane filter along with A4V mutant SOD1, whereas less WT FUS was
detected and no WT SOD1 was detected (Fig. 4.1B). Native gel electrophoresis (20) also
confirmed that FUS protein remained as an oligomeric species under these conditions,
whereas FUS protein prepared in the RIPA buffer migrated faster (Fig. 4.2B). We subjected
the membrane “dots” to trypsin digestion followed by liquid chromatography-tandem mass
spectrometry (LC-MS/MS) using a published protocol (169). A total of 291, 268, and 278
proteins in FUS WT (Supplemental Table 4.1), R495X (Supplemental Table 4.2), and
P525L (Supplemental Table 4.3), respectively, met the protein identification criteria
described in SI Appendix and were considered significant identifications
Proteins identified in the granules were subjected to functional enrichment analysis
using the integrative tool, Enrichr (90, 91). The Gene Ontology (GO): Molecular Function
database (93) and the DISEASES database (94) were utilized for analyzing protein
functions and disease relevance, respectively. The top 20 most significant molecular
function annotations aggregated from the GO: Molecular Function database by Enrichr
revealed a variety of RNA-binding functions associated with WT (Fig. 4.1C) and mutant
FUS (Fig. 4.1D). It is noted that several properties, including translation factor activity,
tRNA binding, and RNA cap binding, are related to protein translation and mRNA
surveillance mechanisms. The top 10 most significant results from the disease-gene
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association analysis for WT and mutant FUS (Fig. 4.3A) show a number of
neurodegenerative diseases, including lateral sclerosis and Charcot–Marie–Tooth disease.
Interestingly, the disease identified with a high significance was Diamond–Blackfan
anemia, a severe ribosomopathy that results in defective protein synthesis(Fig. 4.3B) (170).
This association suggests that proteins identified in FUS granules are likely to be involved
in protein translation. We therefore focused on testing the function of FUS in protein
synthesis and related mRNA surveillance pathways.
We next examined the subcellular localization of critical proteins involved in
protein translation (eIF3, eIF4A1, eIF4G, and rpS6) and mRNA surveillance (eIF4A3) that
were identified in the MS results. In primary cortical neurons transfected with EGFPtagged FUS, eIF4A3 (Fig. 4.1E), eIF3 (Fig. 4.1F), eIF4A1, eIF4G, and rpS6 (Fig. 4.4 A–
C, respectively) were all colocalized with cytoplasmic inclusions of mutant FUS. As a
positive control, mutant FUS inclusions in primary neurons were positive for the stress
granule marker G3BP1 (Fig. 4.4D) as previously reported (22). The immunoprecipitation
(IP) results also demonstrated that eIF3, eIF4G, and eIF4A3 interacted more with the
mutant than WT FUS (Fig. 4.1G), validating the proteomic and colocalization results.
Protein translation is impaired in the presence of mutant FUS

Based on the above proteomic identifications, GO enrichment analysis, and colocalization
of translation machinery to the mutant FUS inclusions, we set out to test whether protein
translation is impaired by ALS mutants of FUS using three independent assays. Utilizing
a translation reporter assay (84), we examined how mutant FUS changed cap-dependent
protein translation. Co-transfection of R495X or P525L mutant FUS with the reporter
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construct resulted in 50% and 70% reductions in the translation of the Renilla reporter
gene, respectively (Fig. 2A). No detectable change was observed in cells transfected with
empty vector (EV) or WT FUS. The control internal ribosomal entry site (IRES)dependent translation of the luciferase gene was not changed (Fig. 4.5A). The second assay
using an in vitro 35S-methionine (35S-Met) incorporation assay to measure translation of
native mRNA showed that 35S-Met incorporation decreased by 25% and 35%,
respectively, in the presence of mutant FUS compared with WT FUS or the EV control
(Fig. 2B). Third, to examine endogenous protein translation, we used the surface sensing
of translation (SUnSET) assay in which puromycin was used as a structural analog of
aminoacyl tRNAs to prevent elongation after being incorporated into the nascent
polypeptide chain (171). N2a cells were transfected with either EV, WT, or mutant FUS
and treated with puromycin. Western blot analysis using an anti-puromycin antibody
showed reduced translation in cells expressing mutant FUS (Fig. 4.5C and D). Finally, we
carried out the SUnSET assay to examine protein translation in the skin fibroblast cells
derived from patients with familial ALS who were carrying R521G or P525R (89) FUS
mutations and from healthy controls with WT FUS (Fig. 4.5E and F). Protein translation
decreased by ∼30% in fibroblast cells from FUS ALS cases. The above results consistently
support that mutant FUS represses protein translation.

We next examined whether FUS inclusions contained puromycinlated proteins.
Immunofluorescence using the same anti-puromycin antibody showed that puromycinlated
proteins were colocalized with mutant FUS inclusions (Fig. 2G), suggesting that translation
complexes are localized in mutant FUS inclusions. Moreover, to test whether mRNA was
also localized to the inclusion, we performed RNA fluorescence in situ hybridization
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(FISH) with two different RNA probes in N2a cells expressing WT or P525L mutant FUS.
A generic Cy3 oligo d(T)21 probe was used to test mature polyadenylated mRNAs (Fig.
4.5H). Mature mRNA was distributed throughout the cytoplasm in cells with EV or WT
FUS. However, a significant accumulation of mRNA in the mutant FUS inclusions was
observed, which is consistent with previous observations (172). FUS has been reported to
regulate the splicing of its own transcript (39); thus, we tested a probe specific to FUS
transcript (exon 4) and found that FUS mRNA was also localized to the mutant FUS
inclusions (Fig. 4.4E). The results support that mutant FUS inclusions were colocalized
with translation machinery and mature mRNAs.
We next examined whether translation initiation is impaired by mutant FUS.
Binding of the initiation factor eIF4E to the 5′ cap of mRNA is the rate-limiting step in
translation initiation where regulation often occurs (173). We performed a 7′methylguanosine (7′MG) pulldown as an in vitro cap-binding assay (174) in the presence
of WT or mutant FUS. After 7′MG pulldown, key members of the preinitiation complex
were observed (Fig. 4.5I). Similar levels of eIF4G, eIF4E, and eIF4A1 were pulled down
regardless of the presence of WT or mutant FUS. Neither WT nor mutant FUS bound to
the 5′ cap. As a negative control, eIF4A3 also did not bind to the 5′ cap. The results suggest
that mutant FUS does not interfere with the binding of the initiation complex to the 5′ cap
structure in the translation initiation stage. Thus, it is likely that translation is disrupted by
mutant FUS after the initiation step, resulting in premature termination.
We hypothesized that prematurely terminated polypeptides resulting from defective
translation in the presence of mutant FUS will be polyubiquitinated and targeted for
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degradation. Therefore, we examined the level of K48-linked polyubiquitination in cells
expressing WT or mutant FUS, since it is the major signal for targeting substrates for
proteasomal degradation. Using an antiK48 polyubiquitination tandem ubiquitin-binding
entity (175), we found that the K48 polyubiquitination level increased ∼1.5- to 1.8- fold in
cells expressing mutant FUS compared with WT FUS and the EV control (Fig. 4.5J and

K). In contrast, the level of K63-linked polyubiquitination, which is involved with other
non-proteasomal processes, did not change with either WT or mutant FUS (Fig. 4.6). These
results collectively support that ALS mutations in FUS cause defects in protein translation.
The NMD pathway is activated by mutant FUS

Protein translation and mRNA surveillance pathways are interrelated(162, 164). It has been
reported that the inhibition of protein translation elongation by cycloheximide (176) can
up-regulate NMD factors and activate NMD (177). Thus, we set to examine whether
mutations in FUS can impact the mRNA degradative pathway NMD. UPF1 (163, 166) and
UPF3b (167) are two critical positive regulators of NMD, and UPF1 phosphorylation (pUPF1) is a critical step in NMD activation (163, 178). We evaluated the levels of UPF1,
p-UPF1, and UPF3b in the skin fibroblast cells derived from six FUS ALS cases and five
healthy controls (Fig. 4.7A). The antibody used for pUPF1 was an anti–phospho-Ser/Thr
ATM/AMR substrate (p-S/T) previously reported (179). Quantitative results show that the
protein level of UPF1 (Fig. 4.7B), p-UPF1 (Fig. 4.7C), and UPF3b (Fig. 4.7D) increased
in patients with ALS compared with healthy controls by 25%, 70%, and 35%, respectively.
Similarly, N2a cells expressing P525L or R495X mutant FUS had increased levels of UPF1
and UPF3b (Fig. 4.8) and p-UPF1 (Fig. 4.9A). The results provide initial evidence that
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NMD activation is elevated in the presence of mutant FUS in the cells of patients with ALS
with mutations in FUS.
We next examined the subcellular localization of endogenous NMD factors in
primary cortical neurons transfected with WT or mutant FUS. The colocalization of mutant
FUS with UPF1 and pUPF1 was demonstrated using two different p-UPF1 antibodies: the
p-S/T antibody used in the Western blot analysis (Fig. 4.7E) and a different antibody
against phosphor-S1089 of UPF1 (180) (Fig. 4.7F). Two additional NMD factors, UPF3b
(Fig. 4.7G) and XRN1 (Fig. 4.10A), were also localized in cytoplasmic inclusions of
mutant FUS in primary neurons. SMG6 was not localized in mutant FUS inclusions serving
as a control (Fig. 4.10B). Similar results were obtained from N2a cells expressing WT or
mutant FUS. Cytoplasmic inclusions of FUS were positive for UPF1 and p-UPF1, UPF3b,
and XRN1 (Fig. 4.9A– C). SMG6 and eRF3b showed little localization to mutant FUS
inclusions in N2a cells (Fig. 4.9D and E). The colocalization of NMD factors in mutant
FUS inclusions further suggests that mutant FUS may impact the NMD pathway.
Since the assembly of key NMD factors with UPF1 is a critical aspect of pathway
activation (181, 182), we next examined the assembly of NMD factors in the presence of
WT or mutant FUS. Endogenous UPF1 IP followed by Western blots for various NMD
factors is shown in Fig. 4.11A. Quantitative analysis showed that the UPF1 interaction with
p-UPF1, UPF3b, the endonuclease SMG6, and FUS increased ∼1.5- to 2.0-fold, with
statistical significance in the presence of mutant FUS (Fig. 4.11B). In addition, the

translation termination factor eRF3b increased in the presence of mutant FUS (Fig. 4.11B).
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Enhanced assembly of NMD factors is additional evidence that NMD was activated by
mutant FUS.
We also tested the interaction of core NMD factors with mRNAs. We treated cells
with bromouridine to label mRNAs, immunoprecipitated the labeled RNA with anti-BrdU
antibody (183), and assessed NMD proteins by Western blot (Fig. 4.11C). Quantitative
analysis showed that higher levels of NMD components responsible for triggering NMD
(eIF4A3 and UPF1) and mRNA degradation (SMG6 and XRN1) were bound to RNAs in
the presence of mutant FUS (Fig. 4.11D). An RNA-binding protein, PABP1, was used as
a loading control and showed similar loading in all samples. The above results consistently
support that the NMD pathway was activated by mutant FUS.
NMD factors are dysregulated in fibroblasts in FUS ALS cases

We demonstrated earlier that two positive regulators of NMD (UPF1 and UPF3b)
and UPF1 phosphorylation increased in the skin fibroblast cells derived from six FUS ALS
cases compared with five healthy controls (Fig. 4.7A–D). The NMD pathway is tightly
regulated by multiple mechanisms, including the molecular brake UPF3a (167). UPF3a
competitively blocks the interaction of UPF3b with UPF2, thus delaying the activation of
NMD. We examined protein levels of UPF3a in six FUS ALS cases (Fig. 4.12A) and found
∼30% lower levels of UPF3a protein in the fibroblast cells from these patients (Fig. 4.12B).
Similarly, UPF3a protein levels decreased in N2a cells overexpressing the R495X and
P525L mutants (SI Fig. 4.13A and B).
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We further examined how the mRNA levels of UPF1, UPF3b, and UPF3a changed
in the FUS ALS cases. The qPCR results show elevated levels of UPF1 (Fig. 4.12C) and
UPF3b (Fig. 4.12D) and decreased levels of UPF3a (Fig. 5E) in the fibroblast cells of FUS
ALS cases. Similar results were obtained for mRNA levels of these factors in N2a cells
expressing WT or mutant FUS (Figs. 4.8C and D and Fig 4.13C). Consistent changes in
both mRNA and protein levels of the pro-NMD factors (UPF1 and UPF3b) and the
negative regulator (UPF3a) illustrate a pattern of NMD dysregulation in the mutant FUSlinked familial patients with ALS, which will contribute to NMD hyperactivation.
UPF1-mediated autoregulation of NMD is impaired in FUS ALS cases

Core NMD factors, including UPF1 and UPF3b, are regulated through an intricate
autoregulatory mechanism, by which their own mRNAs are targeted for NMD (177, 184).
Given the dysregulation of NMD factors as shown above, we hypothesized that the ALS
mutations in FUS disrupt the autoregulatory mechanism of NMD. To test this hypothesis,
we first performed endogenous UPF1 IP followed by qPCR to examine whether the UPF1
protein binds its own mRNA and UPF3b mRNA. Using normal goat serum as a control,
UPF1 protein was specifically pulled down by a UPF1 antibody (Fig. 4.14A). Along with
the UPF1 protein, UPF1 mRNA (Fig. 4.14B) and UPF3b mRNA (Fig. 4.14C) were also
pulled down. We then overexpressed WT, P525L, or R495X mutant FUS in N2a cells and
performed a similar RNA IP experiment (Fig. 4.14D–F). Quantitative analysis showed that,
consistent with earlier results (Fig. 4.7A), higher levels of mutant FUS were pulled down
with the UPF1 protein (Fig. 4.14D). More importantly, lower levels of UPF1 mRNA (Fig.
4.14E) and UPF3b mRNA (Fig. 4.14F) were pulled down along with the UPF1 protein in
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the presence of mutant FUS, suggesting that mutant FUS led to a lower turnover of UPF1
and UPF3b mRNA by NMD. The dampened autoregulatory mechanism through UPF1
binding supports the observation of increases in the mRNA and protein levels of UPF1 and
UPF3b.
To further examine how decay is influenced by FUS mutations, we measured the
UPF1, UPF3b, and UPF3a mRNA levels by qPCR after treating N2a cells expressing WT,
P525L, or R495X mutant FUS with the transcriptional inhibitor actinomycin D. In cells
expressing mutant FUS, the decay of UPF1 (Fig. 4.14G) and UPF3b (Fig. 4.14H) mRNA
was significantly slower than in controls. In contrast, the mRNA decay of the NMD
negative regulator UPF3a was significantly faster in cells expressing mutant FUS (Fig.
4.14I). The results collectively support that the stability of NMD factor mRNA was
dysregulated by mutant FUS in a UPF1-dependent manner (i.e., the NMD autoregulatory
circuit is impaired).
Enhanced decay of NMD substrate in the presence of ALS mutant FUS

Based on the above findings on the dysregulation of NMD factors, we next tested
whether the NMD activity is hyperactivated using four well-characterized NMD reporters
[β-globin and GPX-1 with and without a premature stop codon (PTC)] (185), as well as a
cohort of documented endogenous NMD substrates(186, 187). The levels of all four
reporter transcripts (WT β-globin, WT GPX-1, PTC β-globin, and PTC GPX-1) were
consistently lower in N2a cells expressing mutant FUS than in cells expressing WT FUS
(Fig. 4.15). It is noted that the transcript levels in WT FUS-expressing cells were
unchanged compared with the EV control, with the exception of PTC GPX1 (Fig. 4.15D).
77

The NMD reporter assays support higher NMD turnover of normal and PTC-containing
mRNAs in the presence of mutant FUS.
To better characterize NMD activity, we measured the mRNA levels of three NMD
substrates: ATF3, ATF4, and TBL2 (186, 187). Total mRNA levels of ATF3, ATF4, and
TBL2 (Fig. 4.16A–C) decreased in N2a cells expressing R495X or P525L mutant FUS
compared with cells expressing EV and WT FUS. As a control, mRNA levels of
cyclophilin D did not change (Fig. 4.16D). We next measured the time course of mRNA
levels after transcription inhibition by actinomycin D. The mRNA decay of ATF3, ATF4,
and TBL2 (Fig. 4.16E–G) was significantly faster in cells expressing R495X or P525L
mutant FUS compared with cells expressing WT FUS. As a control, the decay of
cyclophilin D did not differ between cells expressing mutant and WT FUS (Fig. 4.16H).
Furthermore, we examined whether higher levels of these mRNAs were associated with
UPF1. UPF1 protein IP was performed followed by qPCR to measure the amount of UPF1bound mRNAs. While similar levels of UPF1 protein were immunoprecipitated (Fig.
4.16I), higher levels of ATF3, ATF4, and TBL2 mRNAs were bound to UPF1 in the
presence of mutant FUS (Fig. 4.16J–L). All three lines of evidence support the enhanced
NMD decay of these endogenous substrates in cells expressing mutant FUS.
We next examined the mRNA levels of ATF3, ATF4, and TBL2 in fibroblast cells
derived from patients with familial ALS. Indeed, the levels of all three mRNAs were lower
in cells of patients with ALS than in healthy controls with WT FUS (Fig. 4.16M–O). The
results suggest that the NMD activity is induced in clinically relevant samples.
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4.3

Discussion
FUS (8, 157) and other proteins implicated in ALS (70, 158, 159, 188) have been

reported to undergo LLPS and form liquid droplets, which facilitates the formation of
membrane-less RNA-protein granules and inclusions (9, 22, 156). This study started with
developing a method to isolate dynamic FUS-containing granules and identifying their
protein compositions. Enrichment analysis of identified proteins implied that both WT and
mutant FUS are involved in protein translation and mRNA surveillance (Fig. 4.1C and D
and Fig. 4.3). Tight spatiotemporal regulation of protein synthesis in a motor neuron is
critical for its function and survival (189), and reduced protein synthesis can be detrimental
to normal neuronal function (190, 191). Moreover, mRNA surveillance is intimately
integrated into protein translation (162). For instance, eIF4A3 is a core exon junction
complex member that aids in initiating NMD (182). eIF3 is classically known as a critical
initiation factor; however, it is also required for efficient translation termination in the
event of NMD and promotes ribosomal recycling(192, 193). However, it is unknown how
defects in mRNA surveillance are linked to suppression of protein synthesis by ALS
mutation in FUS. The colocalization of eIF4A3 and eIF3 in mutant FUS inclusions (Fig.
4.1E and F) led us to probe how protein translation and NMD are altered by mutant FUS
and to discover the underlying mechanisms.
We used three independent assays to provide direct evidence that mutant FUS
negatively impacted global protein production (Fig. 4.5A–D). Furthermore, the SUnSET
assay also detected significant reduction of protein translation in fibroblast cells derived
from patients with familial ALS with two different FUS mutations (Fig. 4.5E and F). In
addition, mutant FUS inclusions were colocalized with mRNAs (Fig. 4.5H) and
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puromycinylated peptides (Fig. 4.5G), suggesting that such inclusions are sites of defective
protein synthesis with stalled translation complexes. Mutant FUS inclusions have been
reported as stress granule-like with stress granule markers such as G3BP1 and TIA1, but
they display altered dynamics compared with heathy cells with endogenous WT FUS (10,
72, 194, 195). We suggest that the impairment of protein translation as shown in this study
is a functional consequence of the sequestration of the translation machinery in mutant
FUS inclusions.
The above results raised the question how mRNAs resulting from impaired
translation would be handled. It was reported that suppression of translation using
cycloheximide up-regulated proteins involved in the NMD pathway, particularly UPF1 and
UPF3b (177). Our proteomic analysis also suggested that proteins involved in the mRNA
surveillance pathway were enriched in mutant FUS inclusions. We observed increased proNMD proteins UPF1 and UPF3b in fibroblast cells derived from a cohort of patients with
familial ALS bearing two different FUS mutations, R521G and P525R (Fig. 4.7A–D), as
well as in N2a cells expressing mutant FUS (Fig. 4.8). In addition, UPF1 phosphorylation
(Fig. 4.7E and F), NMD complex assembly (Fig. 4.7A and B), and UPF1- mRNA binding
(Fig. 4.7C and D) all increased in the presence of mutant FUS, suggesting an elevated level
of NMD activity as we demonstrated with an NMD reporter assay (Fig. 4.15), in three
endogenous NMD substrates in N2a cells expressing mutant FUS (Fig. 4.16A–H), and in
fibroblast cells from patients with FUS ALS (Fig. 4.16M–O). We rationalized that higher
levels of core NMD factors in mutant FUS inclusions would aid in the degradation of RNAs
associated with prematurely terminated translation complexes, thus playing a protective
role in FUS ALS. A yeast genetic screen identified that UPF1 rescued mutant FUS toxicity
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in Saccharomyces cerevisiae (82), and follow-up studies showed a similar protective effect
of UPF1 overexpression in primary neurons (83) and TDP-43 rat models (196).
Different from UPF1 and UPF3b, UPF3a functions as a molecular brake by
competing with UPF3b for interaction with UPF2 and delaying activation of the pathway
(167). To our surprise, we found that both protein and mRNA levels of UPF3a decreased
in the same cells of patients with familial ALS with mutations in FUS (Fig. 4.12). Loss of
the down-regulatory mechanism could result in aberrant activation of NMD. Moreover,
NMD is regulated by an intricate autoregulatory circuit to prevent overt activation of NMD.
Specifically, the mRNA levels of NMD factors UPF1 and UPF3b are degraded through the
NMD pathway itself(177, 184). Our results from mRNA decay experiments demonstrate
the stabilization of the pro-NMD factors UPF1 and UPF3b and an increased degradation
of the negative regulator UPF3a (Fig. 4.15G–I), suggesting a disruption in the
autoregulatory circuit. These results consistently support a model (Fig. 8) in which the
NMD pathway is dysregulated and hyperactivated in the presence of mutant FUS. It was
reported that UPF1 overexpression could increase the available pool of UPF1 to reactivate
the autoregulatory feedback (184), thus enabling the degradation of UPF1 and UPF3b
mRNAs and dampening the hyperactivation of NMD. This mechanism can provide an
explanation of the reported protective effect of UPF1 overexpression in TDP-43 and FUS
ALS models (82, 83, 196).
Dysregulation of NMD factors can, in turn, contribute to suppressing protein
translation. For instance, besides its function of promoting NMD, UPF3b was reported to
recruit termination factor eRFs to stalled ribosomes and to terminate protein translation
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(197). Interestingly, mutations in UPF3b can result in intellectual disabilities, autism
spectrum disorder, and schizophrenia. These disorders are likely the consequence of
defective NMD in dendrites and neurons, which results in deficient neuronal maturation
and dendritic branching (198, 199).
In mutant FUS ALS, translation suppression and subsequent NMD activation
appear to constitute a vicious cycle, as illustrated in Fig. 8. Increased translation
termination events, potentially due to increased binding of mutant FUS to mRNAs, activate
NMD at higher levels. Furthermore, the autoregulation of NMD is disrupted as the proNMD factors UPF1 and UPF3b increase and the molecular brake UPF3a decreases,
contributing to the hyperactivation of NMD and increased degradation of natural NMD
targets, such as ATF3, ATF4, and TBL2. This hyperactivity resulting from defects in
translation termination may contribute to toxicity in motor neurons (Fig. 4.17). It is noted
that critical steps in this model, including suppressed protein translation (Fig. 4.5E and F);
increased levels of UPF1, p-UPF1, and UPF3b protein (Fig. 4.7A–D) and mRNA (Fig.
4.12C and D); decreased levels of UPF3a protein (Fig. 4.12A and B) and mRNA (Fig.
4.12E); and increased NMD degradation of ATF3, ATF4, and TBL2 mRNAs (Fig. 4.16
M–O), were consistently supported by results from fibroblast cells derived from patients
with familial ALS carrying two different FUS mutations.
Although this study only demonstrated that mutant FUS suppressed global protein
translation, it is conceivable that local translation in dendrites and axon terminals may also
be impaired by mutant FUS. FUS has been demonstrated to be part of RNA transport
granules and to be recruited to activated synapses (33, 66, 200). In cells bearing FUS
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mutations, however, there are defects in synaptic morphology and function (33, 191, 200202). Decreases in proteins required for synaptic maintenance and function may contribute
to an ALS phenotype. Additionally, overactivation of NMD may produce deleterious
effects in stress response pathways, including how cells respond to misfolded proteins,
hypoxia, and DNA damage (161, 177). NMD also functions in fine-tuning the immune
response by degrading mRNAs of proinflammatory factors (203). As neuroinflammation
plays a role in ALS in a non–cell autonomous fashion (204, 205), it is conceivable that
dysregulation of NMD in astrocytes and microglia may also impact the immune response
and contribute to the ALS phenotypes.
In summary, the mechanistic insights gained from this study begin to describe the
role of FUS in protein translation and a critical mRNA quality control pathway, both of
which are required for neuronal maintenance and function. Sequestration of UPF1 in
mutant FUS inclusions, decrease in protein synthesis, NMD hyperactivation, or a
combination of these events likely plays a role in neurodegeneration in ALS. It is noted
that suppressed protein translation (Fig. 4.5E and F), NMD activation (Fig. 4.7A–D),
disrupted NMD autoregulation (Fig. 4.12), and hyperactivity of NMD (Fig. 4.16M– O)
were consistently demonstrated in the fibroblast cells of patients with ALS with mutations
in FUS.
These mechanistic understandings support the notion that regulation of NMD and
protein translation can serve as potential therapeutic targets for future development of new
ALS treatment. The results also have a broader impact, since other RNA-binding proteins
all undergo LLPS and form cytoplasmic granules, including TDP-43, C9ORF72 dipeptide
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repeat, hnRNPA1, and TIA1 (70, 158, 159, 188). Future studies will investigate whether
these proteins, which are implicated in ALS, frontotemporal dementia, and related
disorders, also influence the mRNA quality control pathway and impair protein translation.
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Figure 4.1
Proteomic identification, enrichment analysis, and validation of proteins in WT or mutant
FUS inclusions isolated by membrane filtration. Membrane filtration, followed by dot
blotting of granules isolated using the RIPA buffer (A) or the low-detergent hypotonic lysis
buffer (B), was performed. The molecular function of proteins identified in WT (C) or
mutant (D) FUS inclusions was analyzed using Enrichr software with the GO: Molecular
Functions database. The top 20 most significant (P < 0.05) molecular functions are
represented. Immunofluorescent staining of eIF4A3 (E) and eIF3 (F) in mouse primary
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Figure 4.1 Continued
cortical neurons was performed. Arrows indicate inclusions where proteins of interest are
colocalized. (Scale bars: regular view, 20 μm; zoomed-in views, 5 μm.) (G) FUS IP,
followed by Western blot for translation initiation factors (eIF4AIII, eIF3, and eIF4G) that
were uniquely identified in mutant FUS inclusions.
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Figure 4.2
Native gel electrophoresis of FUS protein in a low detergent hypotonic lysis buffer.
Workflow of the membrane filtration protocol to isolate FUS inclusions using a low
detergent hypotonic lysis buffer. (B). Native gel electrophoresis to assess the migration of
WT FUS and mutant (R495X and P525L) FUS in the low detergent hypotonic lysis buffer.
WT and A4V mutant SOD1 were included as controls.
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Figure 4.3
Diseases associated with proteins identified in WT (A) or mutant (B) FUS inclusions as
analyzed using Enrichr software. The top 10 most significant (p <0.05) diseases are
presented. Blue bars represent neurological or neurodegenerative diseases, while the red
bar represent a ribosomopathy
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Figure 4.4
Colocalization of mutant FUS with selected proteins in mouse primary neurons (A-D) and
RNA (E) in N2a cells. Immunofluorescent staining of eIF4A1 (a), eIF4G (b), RPS6 (c),
and G3BP1 (d) in primary neurons transfected with EGFP-tagged WT or mutant FUS. (e).
RNA FISH using an anti-FUS exon 4 RNA probe. Arrows indicate inclusions where
proteins of interest are colocalized. Scale bars equal to 20 µm in regular views and 5 µm
in zoomed views.
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Figure 4.5
Protein translation is impaired in the presence of mutant FUS. (A) Cap-dependent
translation assay using the luciferase reporter in N2a cells expressing EV, WT, or mutant
FUS. Blue and red bars represent the luminescence of the Renilla cap dependent reporter
and the Firefly luciferase transfection control, respectively. (B) In vitro 35S-Met
incorporation assay using rabbit reticulocyte lysate mixed with N2a cell lysate containing
EV, WT, or mutant FUS. After 1 h of incubation, proteins were precipitated, and
radioactivity was measured using a scintillation counter. Counts were normalized to the
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Figure 4.5 Continued
EV. (C and D) SUnSET assay measuring puromycin incorporated into proteins during
translation in N2a cells expressing EV, WT, or mutant FUS. Western blots of
puromycinylated proteins, FUS, and actin loading control are shown in C. Quantification
in D was performed using the intensity of puromycinylated proteins in each lane to
normalize

against

Actin

and

EV.

(E

and

F)

SUnSET

assay

measuring

puromycinincorporated into proteins during translation in fibroblast cells of patients with
FUS ALS. Western blots of puromycinylated proteins and a GAPDH loading control are
shown in E, and quantification results are shown in F. (G) Immunofluorescent staining of
puromycinylated proteins in N2a cells expressing EV or EGFP-tagged WT or mutant FUS.
Cells were incubated with puromycin for 30 min, fixed using paraformaldehyde (PFA),
and stained with the antipuromycin antibody. (Scale bars: 20 μm.) (H) RNA FISH using a
Cy3-tagged 21-mer oligo d(T) probe in N2a cells expressing WT or mutant FUS. (Scale
bars: 20 μm.) (I) 7′MG pulldown to assess the cap binding and protein translation initiation
in N2a cell lysate containing WT or mutant FUS. Various initiation complex members
(eIF4E, eIF4G, and eIF4AI), FUS, and a negative control (eIF4AIII) were blotted. (J) K48
polyubiquitination in N2a cells expressing EV, WT, or mutant FUS with FUS expression
and actin loading control. (K) Quantification of J using the K48 polyubiquitination
intensity in each lane to normalize against actin and EV. Error bars in the figure represent
SDs for three biological replicates. *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.001. N.S., not
significant. ANOVA with a post hoc Tukey honest significant difference test was used to
determine P values for multiple pairwise comparisons in A, B, D, and K. A Student’s t test
was used to determine P values for simple pairwise comparison in F.
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Figure 4.6
K63-linked polyubiquitination did not change in the presence of mutant FUS. (A). Western
blot for K63 polyubiqitinated proteins in N2a cells transfected with WT or mutant FUS.
(B). Quantification of (a) using intensities in each lane normalized against Actin and
compared to EV. Error bars represent the standard deviation for three biological replicates.
No statistical significance was found among samples using a Students T-test.
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Figure 4.7
Up-regulation of pro-NMD factors in cells of patients with familial ALS and in primary
neurons expressing mutant FUS. (A–D) Levels of pro-NMD factors in patients with ALS
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Figure 4.7 Continued
Fig. 4.17 Continued carrying the R521G or P525R mutation and in control subjects with
WT FUS. Western blots of UPF1, p-UPF1, UPF3b, and actin control were performed (A),
and quantification of UPF1 (B), p-UPF1 (C), and UPF3b (D) was normalized against actin
and obtained from three replicates. Error bars represent the SD between individuals.
Quantifications were compared with healthy controls using a Student’s t test. *P ≤ 0.05;
**P ≤ 0.005. (E–G) Immunofluorescent staining of UPF1, p-UPF1, and UPF3b in mouse
primary neurons transfected with EV, EGFP-tagged WT, or mutant FUS at day 4 of in vitro
culture. (E) Immunofluorescent staining of UPF1 and p-UPF1 using an anti–p-S/T
ATM/AMR substrate antibody. (F) Immunofluorescent staining of p-UPF1 using an
antibody against phosphor-S1089 in UPF1. (G) Immunofluorescent staining of UPF3b.
Arrows indicate inclusions where proteins of interest are colocalized. (Scale bars: regular
views, 20 μm; zoomed-in views, 5 μm.).
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Figure 4.8
Increased protein (A-B) and mRNA (C-D) levels of UPF1 and UPF3b in N2a cells
expressing mutant FUS. (A). N2a cells were transfected with WT or mutant FUS and the
protein levels of UPF1 and UPF3b were assessed by SDS-PAGE followed by Western blot.
(B). Quantification of UPF1 and UPF3b Western blot as normalized to Actin and compared
to the EV. (C-D) qPCR quantification of the mRNA levels of UPF1 (c) and UPF3b (d) in
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Figure 4.8 continued
N2a cells transfected with WT or mutant FUS. Quantification was performed using the
∆∆cT method and presented as fold changes as compared to EV. Error bars represent
standard deviations for three biological replicates. P values are determined using a Students
T-test. * p≤0.05, ** p≤0.005, and *** p≤0.001.
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Figure 4.9
Immunostaining of NMD factors and FUS in N2a cells. N2a cells were transfected with
empty vector (EV), or EGFP-tagged WT or mutant FUS, and stained for endogenous UPF1
(A), phospho-UPF1 (A), UPF3b (B), XRN1 (C), SMG6 (D), and eRF3b (E), respectively.
All scale bars equal to 20 µm.
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Figure 4.10
Immunostaining of XRN1 (A), SMG1 (B) and SMG6 (C) in mouse primary neurons.
Mouse primary cortical neurons were transfected with empty vector (EV), or EGFP-tagged
WT or mutant FUS and stained for the indicated proteins. Arrows indicate inclusions where
proteins of interest are colocalized. Scale bars equal to 20 µm in regular views and 5 µm
in zoomed views.
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Figure 4.11
Interaction of NMD factors with UPF1 and RNAs increased in the presence of mutant
FUS. (A and B) NMD factors coprecipitated with endogenous UPF1 from N2a cells
expressing EV, WT, or mutant FUS. Immunoblots of UPF1, p-UPF1, eRF3b, UPF3b,
SMG6, and 3Å~ FLAG-FUS are shown in A, and quantitative results are shown in B.
Protein intensities were normalized to corresponding UPF1 bands and compared with EV.
(C and D) NMD factors coprecipitated with BrdU-containing RNAs. N2a cells expressing
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Figure 4.11 Continued
EV, WT, or mutant FUS were incubated with 1 μM BrdU, and RNAs were UV cross-linked
to proteins. BrdU IP was performed using an anti-BrdU antibody, followed by Western
blots for UPF1, eIF4A3, XRN1, SMG6, FUS, PABP1, and actin. BrU, bromouridine.
Quantification of proteins in C is shown in D. Proteins were normalized to the loading
control, PABP1, and compared with EV. The purple, green, blue, and red bars represent
EV, WT FUS, R495X FUS, and P525L FUS, respectively. Error bars represent SDs for
three biological replicates. *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.001. Quantifications were
compared with EV using a Student’s t test.
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Figure 4.12
Down-regulation of the NMD negative regulator UPF3a in cells of patients with familial
ALS. (A and B) Protein levels of the NMD negative regulator UPF3a in six patients with
ALS and five control subjects, as shown in Fig. 3 A and B. Western blots of UPF3a and an
actin control (A) and quantification of UPF3a normalized against actin (B) are shown. (C–
E) Quantification of mRNA levels of dysregulated NMD factors. qPCR of UPF1 (C),
UPF3b (D), and UPF3a (E) was performed using the cycle threshold method and is
presented as the fold change in patients with ALS versus controls. Actin was used to
normalize cycle threshold values. Error bars represent the SD between individuals. *P ≤
0.05; **P ≤ 0.005. Quantifications were compared with healthy controls using a Student’s
t test.
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Figure 4.13
Decreased protein (A-B) and mRNA (C) levels of UPF3a in N2a cells expressing mutant
FUS.N2a cells were transfected with empty vector (EV), or WT or mutant FUS and the
protein levels of UPF3a were assessed by SDS-PAGE followed by Western blot. (B).
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Fig. 4.13 Continued
Quantification of UPF3a Western blot as normalized to Actin and compared to the EV.
(C). qPCR quantification of the mRNA levels of UPF3a in N2a cells transfected with WT
or mutant FUS. Quantification was performed using the ∆∆cT method and presented as
fold changes as compared to EV. Error bars represent standard deviations for three
biological replicates. ** p≤0.005, and *** p≤0.001. Students T-test was used to determine
p values.
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Figure 4.14
Disruption in the NMD autoregulation loop. Endogenous UPF1 IP from N2a cells was performed, followed by Western blot (A)
and qPCR measurement of UPF1 (B) and UPF3b (C) mRNAs. N2a cell lysate was subjected to IP using normal goat serum
(NGS) or goat anti-UPF1 antibody. The IP samples were aliquoted for Western blot (A) and qPCR quantification (B and C)
comparing RNA coprecipitated with UPF1 protein versus NGS control. UPF1 IP from N2a cells expressing EV, WT, or mutant
FUS was performed, followed by Western blot (D) and qPCR measurement of UPF1 (E) and UPF3b (F) mRNAs. UPF1, FUS,
and GAPDH were assessed by Western blot, as shown in D. qPCR quantification was normalized to UPF1 protein precipitate

Figure 4.14 Continued
and presented as fold change compared with EV. Turnover rates of UPF1 (G), UPF3b (H),
and UPF3a (I) mRNAs in N2a cells expressing EV, WT, or mutant FUS are shown.
Actinomycin D or DMSO control was added 2 or 4 h before harvesting for RNA isolation.
Individual mRNAs of interest were quantified by qPCR, normalized against RPL13a, and
presented as fold change versus DMSO treatment over time. Error bars represent the SD
from three replicates. *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.001. N.S., not significant. ANOVA
with a post hoc Tukey honest significant difference test was used in E–I, and a Student’s t
test was used in B and C.
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Figure 4.15
The NMD activity in the presence of WT or mutant FUS using an NMD reporter assay.
NMD activity assay was carried out using the WT β -globin (A), WT GPX-1 (B), β-globin
PTC (C), or GPX-1 PTC (D) reporter. N2a cells were cotransfected with empty vector
(EV), or WT or mutant FUS and an NMD reporter as indicated. The levels of the indicated
reporter transcript were quantified by qPCR using the ∆∆cT method. The fold changes as
compared to EV are presented. ANOVA with post hoc Tukey HSD test was used to
determine p-values for multiple pair-wise comparisons.

106

Figure 4.16
Enhanced NMD activity in the presence of mutant FUS.The mRNA levels of ATF3 (A),
ATF4 (B), TBL2 (C), and cyclophilin D (D) in N2a cells transfected with EV, WT, or
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Figure 4.16 Continued
mutant FUS were determined. The levels of the indicated mRNA were quantified by qPCR
using the cycle threshold (ΔΔCT) method, and the fold changes compared with WT are
presented. Turnover rate of ATF3 (E), ATF4 (F), TBL2 (G), and cyclophilin D (H) mRNAs
in N2a cells expressing EV, WT, or mutant FUS after treatment with actinomycin or
DMSO control. Individual mRNAs of interest were quantified by qPCR, normalized
against RPL13a, and presented as fold change versus DMSO treatment over time. Error
bars represent the SD from three replicates. (I–L) Amount of ATF3, ATF4, and TBL2
mRNA bound to the UPF1 protein. N2a cells were cotransfected with EV, WT, or mutant
FUS and an NMD reporter as indicated. After UPF IP, Western blot (I) demonstrates levels
of UPF1 in lysate and IP samples. The levels of ATF3 (J), ATF4 (K), and TBL2 (L) mRNA
in the UPF1 IP samples were quantified by qPCR using the ΔCT method. The fold changes
normalized to WT are presented from three replicates. The mRNA levels of ATF3 (M),
ATF4 (N), and TBL2 (O) in fibroblast cells derived from patients with familial ALS
carrying FUS mutations and healthy WT controls are shown. *P ≤ 0.05; **P ≤ 0.005; ***P
≤ 0.001. N.S., not significant. ANOVA with a post hoc Tukey honest significant difference
test was used to determine P values in A–L. A Student’s t test was used to determine P
values in M–O.
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Figure 4.17
Model illustrating how mutant FUS impairs NMD regulation and suppresses protein
translation. (A) Normal translation and basal NMD under physiological conditions with
WT FUS. (B) Mutant FUS has greater binding ability to mRNAs and associated proteins,
including UPF1, leading to ribosomal stalling, translation termination, and subsequent
activation of NMD. Up-regulation of pro-NMD factors (UPF1 and UPF3b) and downregulation of the molecular brake (UPF3a) cause the loss of autoregulation and
hyperactivity of NMD. pA, poly(A) tail.
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CHAPTER 5. THE ROLE OF ENDOGENOUS FUS IN NONSENSE MEDIATED DECAY
5.1

Introduction
FUS is a member of the FET family of DNA- and RNA-binding proteins that are

primarily localized to the nucleus. FUS forms dynamic ribonucleoprotein granules in the
nucleus to maintain efficacious transcription and splicing (2, 13, 20, 21, 29, 37-39, 45, 52,
53, 113, 160, 169, 206-209). In contrast, ALS-related mutations in FUS cause its
accumulation in the cytoplasm and the formation of inclusion bodies. These granules can
lead to the formation of inclusion bodies and potentially contribute to neurotoxicity (2, 3,
156). However, whether the formation of these inclusions and neurotoxicity are due to loss
of function or a toxic gain of function when FUS is mutated remains to be understood. To
clarify the cellular consequences of FUS mutations, utilization of FUS knockout (KO)
systems are critically important. FUS KO cells and mice provide a platform to observe the
biochemical and physiological outcomes of the loss of FUS in a wide variety of cell types
across the central nervous system.
Understanding the repercussions of FUS (KO) in a neuronal system are essential
for determining FUS’ major role causing ALS. While FUS KO result in embryonic lethality
(210-212), conditional KO after birth does not cause motor neuron dysfunction, as
homozygous mice did not exhibit an ALS phenotype (210). FUS KO has been
demonstrated to have detrimental impacts on the behavior and brain structure of mice
(210). Affected mice displayed hyper-activity and anxiety-like behavior but did not display
defective Gem morphology previously observed (206, 207, 213). Demonstration of an FTD
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phenotype without a disruption in motor function is illustrative of important transcriptome
changes that may be brain-region and cell-type specific (210).
KO of FUS has been used as a cell-based tool to better understand if ALS-related
mutations in FUS contribute to a gain or loss of function of the protein. FUS’ role in
splicing has been well defined using KO cells and animals. Splicing changes that occur
when FUS is knocked out has been well described and compared in detail to changes that
occur in FUS mutants (206). Overall, loss of FUS results in gross changes to the
transcriptome due to loss of Gems, and therefore reduced levels of snRNPs. Reduced
snRNP levels are likely to contribute to changes in gene expression. In this regard, loss of
FUS greatly mimics FUS mutations, as the presence of FUS in the nucleus is required for
normal splicing. RNA seq using FUS knockdown in human fibroblasts demonstrates
reduction of splicing factors, as well as other important genes for neuronal function (40).
These data imply that mutations in FUS result in a nuclear loss of function.
Recently, studies to examine FUS’ cytoplasmic role have begun to demonstrate its
importance in translation and maintenance of RNA stability (67, 214). These studies bring
additional complexity as to whether mutations in FUS are a loss of function or toxic gain
of function. For example, consistent changes in gene expression lead to changes in
particular protein levels. WT FUS and ALS mutants have been demonstrated to interact
with translation factors (214) and FUS inclusions have been demonstrated to hinder
translation in both cellular and animal models (67, 214). Mechanistically, how FUS
regulates and interacts with proteins within these processes has remained to be better
defined, but deeper biochemical studies may yield clues as to the nature of their interaction
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and how they contribute to ALS. Additionally, studies exploring mutant FUS’ role in
activation of mRNA degradative pathways raised the question as to whether WT FUS plays
a role in maintaining the balance of nonsense mediated decay (NMD). NMD serves as a
post-initiation regulatory step for protein translation and is initiated due to errors and
regulatory elements within mRNA, as well as when protein translation is stalled (164).
In our exploration of how mutations in FUS initiate NMD, we observed a novel
interaction between WT FUS and UPF1. However, overexpression of WT FUS does not
perturb the pathway, it is possible that endogenous FUS may be important for regulation
of UPF1 activity and NMD. Based on publicly available CLIP data (215), FUS has been
reported to interact with UPF1 mRNA, as well as the mRNA of UPF2, UPF3a, UPF3b,
SMG1, SMG5, SMG6, SMG7, and SMG8. It is worth noting that these RNA species are
auto-regulated through the NMD pathway. Therefore, we hypothesized that one of FUS’
endogenous functions is to aid in autoregulation of NMD. Using N2A stable FUS knockout
cells (termed NCF in this chapter), we probed for basic changes in NMD regulation and
function. Specifically, we examined the steady state levels of NMD factors and substrates,
UPF1 interaction with effector proteins, and the stability of NMD factors.

5.2

Results
FUS Binds NMD Factor mRNA

The availability of large data sets through CLIPdb has allowed us to examine
potential mRNA targets that FUS protein may bind (215). We initially probed the database
for FUS’ interaction with NMD factor mRNA that is also subject to autoregulation through
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the pathway. We found that FUS has been reported to bind to UPF1, UPF2, UPF3a, UPF3b,
SMG1, SMG5, SMG6, SMG7, and SMG8 mRNA. The stabilities mRNA species are
autoregulated through the NMD pathway (184). Our first experimental step in
understanding endogenous FUS’ role in NMD was to confirm the CLIPdb FUS/mRNA
interaction results (215). We selected five critical NMD factor’s mRNA to examine: UPF1,
UPF2, UPF3b, SMG6, and SMG7. Using a FUS RNA IP, we immunoprecipitated FUS
protein and using rt-qPCR, we measured the mRNA levels of the selected RNA species
bound to FUS. We demonstrated that the results found in the CLIP data base were
consistent with our qPCR data, with the exception of UPF1 mRNA (data not shown), which
we found did not interact with FUS. This may be due to cell type differences, however.
FUS bound UPF3b (Fig. 5.1A), UPF2 (Fig. 5.1B), SMG6 (Fig. 5.1C), and SMG7 mRNA
(Fig. 5.1D). These results indicate that FUS may regulate NMD factors levels through
mRNA binding, with the exception of UPF1. List of additional primers used are attached
in Supplemental table A.
FUS Binds NMD Substrate mRNA

In addition to using the CLIP database to identify NMD factor mRNA that binds
FUS, we also probed for NMD substrates that may interact with the FUS protein. We
searched CLIPdb (215) and found that FUS protein was previously published to bind
ATF3, ATF4, and TBL2 mRNA. We next wanted to examine FUS’ binding with natural
NMD substrate mRNA: ATF3, ATF4, and TBL2 experimentally. We previously found that
ALS-related mutations in FUS facilitated NMD decay these substrates (214), however the
interactions between FUS and these mRNA substrates was not examined. Using a FUS
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RNA immunoprecipitation, we pulled-down mRNA bound to FUS protein and used rtqPCR to measure the levels of mRNA binding. We discovered that FUS binds all three of
these mRNA species. While the levels of binding are not particularly high in ATF3 (Fig.
Fig. 5.2A) and TBL2 (Fig. 5.2C), they are still significantly higher than the FUS KO (NCF)
background control. FUS bound ATF4 mRNA as well (Fig. 5.3B). It should be noted that
the qPCR data presented were generated from the same set as the previous set of FUS RNA
IPs (Fig. 5.1) and therefore have the same western blot demonstrating effective
immunoprecipitation (Fig 5.2D). We conclude that endogenous FUS binds NMD substrate
mRNA, however, a more comprehensive list of substrates may be identified through RNASeq. Overall, we can conclude that FUS does bind these NMD substrates and therefore,
may play a role in maintaining their regulation and gene expression.
FUS Knockout Downregulates Pro-NMD Factor Proteins

Following up on FUS’ binding to NMD factor mRNA, we hypothesized that FUS
would have an influence on the steady state levels of the selected proteins. Thus, we
examined whether the steady state protein levels are changed when FUS is knocked out
and whether they are rescued when FUS is re-expressed. Western blots demonstrated
modest reductions of SMG1, SMG5, SMG6, SMG7 (Fig. 5.3A), UPF1, UPF3a, and UPF3b
(Fig. 5.3B) protein levels. Protein levels of eIF4A3, RNPS1, and actin (Fig. 5.3C) did not
change at the protein level. Interestingly, XRN1 proteins was significantly reduced in the
FUS KO cells by approximately 10% (Fig. 5.3C). Western blots were quantified and
represented Fig. 5.3D. We observed a rescue of protein levels when FUS was re-expressed,
strongly indicating that knockout of FUS is directly responsible for reductions in protein
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levels. These data imply that FUS’ interaction with NMD factor mRNA (Fig. 5.1) may play
a role in regulating the protein levels of NMD factors through RNA binding.
FUS KO Reduces NMD Complex Assembly

Decreased protein levels of NMD factors led us to question if the NMD pathway
activity is reduced when FUS is knocked out. A readout for the pathway activity is to
examine NMD complex formation. Thus, we performed a UPF1 IP and western blotted for
core NMD factors. We observed reduced interaction between UPF1 and UPF3b, SMG6,
SMG7, and UPF2 (Fig. 5.4A, B) indicating that NMD complex levels in FUS KO cells are
reduced as compared to WT N2A cells but rescued by re-expressing WT FUS. These data
suggest two possible reasons for a reduction in complex assembly: 1) FUS protein is
required for complex formation and/or 2) FUS KO’s reduction in NMD factor protein
levels directly translates into reduced complex formation. It appears as though NMD
activity may be suppressed due to reduced levels of effector proteins and their effector
complexes.
FUS Knockout Downregulates Pro-NMD Factor mRNA

To determine if FUS KO’s changes in NMD factor protein levels are due to
decreased mRNA levels, we examined the steady-state levels of NMD factor mRNA. We
performed rt-qPCR to examine mRNA levels of UPF1, UPF2, UPF3b, and SMG1 (Fig.
5.5A-D). We observed depressed mRNA levels of NMD factors, with modest to complete
rescue by re-expression of WT FUS. Levels of XRN1, eIF4A3, and CyclophilinD mRNA
(Fig. 5.5E-G) did not change. These data suggest that FUS binds NMD factor mRNA and
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maintains mRNA levels, and that KO results in reduced mRNA and protein levels. We
conclude that FUS is required for maintenance of NMD factor mRNA levels.
Stability of NMD Factors is Unchanged when FUS is Knocked Out

As we observed reductions in steady state levels of NMD factor mRNA and
proteins, we hypothesized that these mRNAs would have reduced stability and higher
turnover in the absence of FUS. We examined the stability of UPF1, UPF3b, SMG6, and
SMG7. Using an actinomycin D time course assay paired with rt-qPCR, we found that the
stability of UPF1, UPF3b, SMG6, and SMG7 are unchanged (Fig. 5.6A-D), and therefore
the decay of these NMD factors was not impacted by the loss of FUS. These results were
unexpected but yielded very interesting information on how FUS regulates NMD. These
data, in combination with the reduced steady state mRNA levels (Fig 5.5) suggest that FUS
regulates NMD factor expression at the transcriptional level. Furthermore, this stability
data and steady state data demonstrate that the nuclear function of FUS (e.g. transcription
regulation) may impact its cytoplasmic functions and pathways (e.g. regulation of NMD or
translation).
FUS KO Reduces UPF1 Binding to NMD Factor mRNA

In previous studies we identified WT FUS as a novel binding partner for UPF1
(214). UPF1 is a dynamic protein that acts as an RNA helicase with ATPase activity that
regulates its binding affinity to RNA. Additionally, it serves as a binding platform for other
NMD effector proteins (162, 163). Better understanding of the dynamics between FUS and
UPF1 may help us understand how FUS participates in NMD. UPF1’s RNA binding ability
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is critical to its function in triggering NMD (185). To understand how FUS KO impacts
UPF1’s RNA binding ability, we performed a UPF1 RNA IP. UPF1 protein was used as
bait and was pulled down with bound RNA. We used rt-qPCR to measure the binding of
the following mRNA species: UPF1, UPF3b, UPF2, SMG6, and SMG7 (Fig. 5.7A-E). FUS
KO reduced UPF1 binding to all selected mRNA, including FUS mRNA itself. Moreover,
re-expression of WT FUS rescued UPF1 binding to the selected mRNA. Western blot
confirming UPF1 Immunoprecipitation can be found in Fig 5.9 since the same UPF1 RNA
IP samples were used for both sets of experiments in Fig 5.7 and 5.9.
It is likely that FUS plays an important role in mediating UPF1/RNA interaction.
Based on our selected mRNA, it is possible, that NMD autoregulation is shifted toward
pathway upregulation by FUS KO. Upregulation of NMD would be logical due to splicing
defects that occur when FUS is lost. However, FUS KO could also cause reduced
transcription of NMD factors. Thus, the data are complex and cannot be explained simply
by shifted NMD autoregulation alone.
NMD Substrate mRNAs are Stabilized when FUS is Knocked Out

Our observation of reduced complex NMD formation (Fig 5.4) led us to question
if the NMD pathway is functional when FUS is knocked out. Thus, we examined the
stability of selected NMD substrates ATF3, ATF4, and TBL2 in FUS WT, KO, and reexpression cells. Using an actinomycin D time course assay paired with rt-qPCR, we found
that ATF3, ATF4, and TBL2 (Fig. 5.8A-C) were stabilized when FUS is knocked out,
suggesting reduced NMD activity. The stability of CyclophilinD, our control, remained
consistent regardless of the presence of FUS (Fig. 5.8D). Additionally, re-expression of
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FUS rescued the stabilization of these RNA species. These data suggest that FUS KO does
result in reduced NMD activity. Downregulation of NMD factors and associated
complexes would result in increased expression of ATF3, ATF4, and TBL2 through their
stabilization.
FUS KO Reduces UPF1 Binding to NMD Substrate mRNA

Probing into UPF1’s binding ability to NMD substrates when FUS is knocked out
may help us understand if FUS plays a role in target differentiation, thus we performed a
UPF1 RNA IP to understand how FUS KO impacts UPF1’ RNA binding ability to NMD
substrate mRNAs. After UPF1 protein was pulled down we used rt-qPCR to measure the
binding of the following mRNA species: ATF3, ATF4, and TBL2. FUS KO reduced UPF1
binding to all selected mRNAs (Fig. 5.9A-C), re-expression rescued UPF1 binding. It is
noted that the UPF1 RNA IP in Fig 5.7 and 5.9 share the same western blot. The results
suggest that the interaction between UPF1 and NMD substrates may require FUS for
efficacious NMD, consistent with increased mRNA stabilities in Fig 5.8.
Natural NMD substrate levels are in influenced by FUS KO

With the reduced mRNA and protein levels of NMD factors (Fig. 5.3 and 5.5),
reduced NMD complex formation (Fig. 5.4), reduced UPF1 binding to NMD substrates
(Fig. 5.9), and increased mRNA stabilities of NMD substrates (Fig. 5.8), we would expect
increased mRNA levels of these NMD substrates when FUS is knocked out. Thus, we
measured the steady state levels of the NMD substrates previously published (214): ATF3,
ATF4, and TBL2, as well as ATF6 and GADD45B (186). Surprisingly, the steady state
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mRNA levels appear to be complex. For ATF3 (Fig. 5.10A), there was a modest, but
insignificant increase in mRNA levels and reduction when FUS was re-expressed. While
this followed the proposed trend, it was not statistically significant. ATF4 and TBL2 (Fig.
5.10B, D) saw increased mRNA levels when FUS was knocked out, but upon re-expression
mRNA levels increased further. ATF6 levels decreased following FUS KO and transcript
levels partially recovered following rescue (Fig. 5.10C). GADD45B (Fig. 5.10E)
demonstrated reduction of mRNA levels when FUS was knocked out and then further
reductions when FUS was re-expressed. These results obviously are inconsistent with the
above hypothesis solely based on NMD alone. The results suggest that FUS’ influence over
the expression specific genes is more complicated than regulation of mRNA stability
through NMD alone. It is likely that FUS’ ability to regulate gene expression is a genespecific mixture of its function in transcription, RNA splicing, RNA export, translation,
and stability.

5.3

Conclusions and Future Directions for FUS KO/ NMD Study
Overall, the results of this small study are promising, however, more work needs to

be done to fully develop a mechanism by which endogenous FUS regulates NMD factor
expression and its impact on downstream substrate stability. In our preliminary
examination of FUS’ role, we aimed to demonstrate its function in modulating the
expression NMD factor genes through the NMD pathways autoregulation. However, FUS’
cellular function is complex and encompasses nearly every aspect of canonical gene
expression: transcription, splicing, translation, and mRNA stabilization. We were able to
establish that FUS likely controls the expression of major NMD factors through
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transcription, as KO of FUS does not impact the stability of their mRNA but reduces the
steady levels of mRNA and proteins. We observed increased stability of endogenous NMD
substrate, however, steady state levels of these mRNAs indicate that FUS may play a more
intricate role in their expression as well.
Future studies to expand on these data should include both quantitative LC MS/MS
and RNA-seq studies to examine changes in the protein and mRNA repertoire that occur
when FUS is knocked out. Recently, studies exploring why motor neurons are uniquely
susceptible to degeneration demonstrated vast differences in the proteome compared to
oculomotor neurons, a subtype of motor neurons unaffected by disease. Downregulation
of “supersaturated” proteins, including ion channels and proteins related to RNA
metabolism contribute to neuronal dysfunction (216). Comparison of proteins and mRNA
lost upon FUS KO to those known to be supersaturated may provide important clues as to
which proteins are most heavily impacted. Functional and mechanistic experiments
following up these large-omic studies may include deeper dives into molecular pathways
negatively impacted by both loss of FUS and ALS.
Additionally, studies exploring the biochemical and molecular interaction between
UPF1 and FUS will be critical for understanding UPF1’s newly described role in the
nucleus and in ALS(217). A recently published study illustrates a novel aspect of UPF1
function in the nucleus that seems to mirror FUS’. Like FUS, UPF1 has been demonstrated
to cluster with nascent transcripts, and RNAP II and III (14, 106, 217). Similarly, UPF1
demonstrated to be important for efficient polyadenylation and release of new transcripts,
RNP assembly, and RNA export. Deeper exploration into the interactions between UPF1
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and WT or mutant FUS (214) (Fig 5.9D) will likely yield important information as to how
FUS directly plays a role in NMD and how mutants disturb the pathway.
We conclude that endogenous FUS plays an important role in mediating NMD
activity through transcriptional regulation of NMD factors (Fig 5.3, 5.5, and 5.6). This is
supported by the stabilization of endogenous NMD substrates ATF3, ATF4, and TBL2
when FUS is knocked out (Fig 5.8). In addition, FUS appears to regulate mRNA levels at
different levels in fine tuning the final mRNA and protein levels of these genes.
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Figure 5.1 Endogenous FUS binds key NMD factor mRNA
Wild type N2a cells and N2a FUS knockout (NCF) cells were lysed and FUS was
immunoprecipitated. mRNA bound to endogenous FUS was measured using rt-qPCR (AD). The levels of the indicated mRNA were quantified by qPCR using the cycle threshold
(ΔΔCT) method, and the fold changes compared with NCF are presented. *P ≤ 0.05; ***P
≤ 0.001. A Student’s t test was used to determine P values.
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D.

Figure 5.2 Endogenous FUS binds NMD substrate mRNA
Wild type N2a cells and N2a FUS knockout (NCF) cells were lysed and FUS was
immunoprecipitated. mRNA bound to endogenous FUS was measured using rt-qPCR (AC). The levels of the indicated mRNA were quantified by qPCR using the cycle threshold
(ΔΔCT) method, and the fold changes compared with NCF are presented. *P ≤ 0.05; **P
≤ 0.005; ***P ≤ 0.001. A Student’s t test was used to determine P values.
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Figure 5.3 Endogenous FUS is required for normal expression of NMD factor protein
NMD factors were blotted for in WT N2a, NCF, and FLAG FUS rescue cells to examine
their steady state levels. Immunoblots of the following proteins are shown: SMG1, SMG5,
SMG6, and SMG7 (A), UPF1, UPF2, UPF3b, and UPF3a (B), and XRN1, eIF4A3,
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Figure 5.3 continued
RNPS1, endogenous FUS, FLAG FUS, and Actin (C). Quantitative results are shown in
D. Protein intensities were normalized to actin and compared with N2a. *P ≤ 0.05; **P ≤
0.005; ***P ≤ 0.001. A Student’s t test was used to determine P values.
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Figure 5.4 Endogenous FUS is required for assembly of NMD factor complexes
NMD factors coprecipitated with endogenous UPF1 from WT N2a, NCF, and FLAG FUS
rescue cells. Immunoblots of UPF1, p-UPF1, UPF3b, SMG6, SMG7, endogenous FUS,
FLAG-FUS, and GAPDH are shown in A, and quantitative results are shown in B. Protein
intensities were normalized to corresponding UPF1 bands and compared with N2a. *P ≤
0.05; **P ≤ 0.005; ***P ≤ 0.001. A Student’s t test was used to determine P values.
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Figure 5.5 Endogenous FUS is required for normal expression of NMD factor mRNA
mRNA from WT N2a, NCF, and FLAG FUS rescue cells were collected and steady state
levels measured using rt-qPCR (A-G). The levels of the indicated mRNA were quantified
by qPCR using the cycle threshold (ΔΔCT) method, and the fold changes compared with
N2a are presented. *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.001. A Student’s t test was used to
determine P values.
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Figure 5.6 NMD factor mRNA stability is unchanged when FUS is Knocked Out
Turnover rates of UPF1 (A), UPF3b (B), SMG6 (C), and SMG7 (D) mRNAs in WT N2a,
NCF, or FLAG FUS rescue cells. Actinomycin D or DMSO control was added 1, 2, or 3
hr before harvesting for RNA isolation. Individual mRNAs of interest were quantified by
qPCR, normalized against RPL13a, and presented as fold change versus DMSO treatment
over time. Error bars represent the SD from three replicates. ANOVA with a post hoc
Tukey honest significant difference test was used.
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Figure 5.7 FUS KO Reduces UPF1 Binding to NMD Factor mRNA
WT N2a, NCF, or FLAG FUS rescue cells lysate was subjected to IP using normal goat
serum (NGS) or goat anti-UPF1 antibody. The IP samples were aliquoted for Western blot
and qPCR quantification comparing RNA coprecipitated with UPF1 protein versus NGS
control. UPF1 IP from WT N2a, NCF, or FLAG FUS rescue cells was performed, followed
by Western blot (Fig. 5.10) and qPCR measurement of UPF1 (A), UPF2 (B), UPF3b (C),
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Figure 5.7 continued
SMG6 (D), and SMG7 (E) mRNAs. The levels of the indicated mRNA were quantified by
qPCR using the cycle threshold (ΔΔCT) method, and the fold changes compared with N2a
are presented. *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.001. N.S., not significant. ANOVA with
a post hoc Tukey honest significant difference test was used to determine P values.
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Figure 5.8 NMD substrate mRNA is stabilized when FUS is Knocked Out
Turnover rates of ATF3 (A), ATF4 (B), TBL2 (C), and CyclophilinD (D) mRNAs in WT
N2a, NCF, or FLAG FUS rescue cells. Actinomycin D or DMSO control was added 1, 2,
or 3 hr before harvesting for RNA isolation. Individual mRNAs of interest were quantified
by qPCR, normalized against RPL13a, and presented as fold change versus DMSO
treatment over time. Error bars represent the SD from three replicates. *, # P ≤ 0.05; **,
##P ≤ 0.005; ***, ###P ≤ 0.001. A Student’s t test was used to determine P values. *
represent significance compared to N2a, # represent significance compared to NCF.
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Figure 5.9 UPF1 Binding to NMD Substrate mRNA is Reduced When FUS is Knocked
Out
WT N2a, NCF, or FLAG FUS rescue cells lysate was subjected to IP using normal goat
serum (NGS) or goat anti-UPF1 antibody. The IP samples were aliquoted for Western blot
and qPCR quantification comparing RNA coprecipitated with UPF1 protein versus NGS
control. UPF1 IP from WT N2a, NCF, or FLAG FUS rescue cells was performed, followed
by Western blot (Fig. 5.10) and qPCR measurement of ATF3 (A), ATF4 (B), and TBL2
mRNAs. UPF1, FUS, and GAPDH were assessed by Western blot, as shown in D. The
levels of the indicated mRNA were quantified by qPCR using the cycle threshold (ΔΔCT)
method, and the fold changes compared with N2a are presented. *P ≤ 0.05; **P ≤ 0.005;
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Figure 5.9 continued
***P ≤ 0.001. N.S., not significant. ANOVA with a post hoc Tukey honest significant
difference test was used to determine P values.
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Figure 5.10 Natural NMD substrate levels are in influenced by FUS KO
mRNA from WT N2a, NCF, and FLAG FUS rescue cells were collected and steady state
levels measured using rt-qPCR (A-E). The levels of the indicated mRNA were quantified
by qPCR using the cycle threshold (ΔΔCT) method, and the fold changes compared with

134

Figure 5.10 continued
N2a are presented. *P ≤ 0.05; **P ≤ 0.005; ***P ≤ 0.001. N.S., not significant. ANOVA
with a post hoc Tukey honest significant difference test was used to determine P values.
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